var title_f5_10_5280="Axial view sesamoids";
var content_f5_10_5280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Axial view of the sesamoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A fracture is not apparent on this view because the fracture lies in the same plane as the x-ray film and there is no displacement. This and other views could prove valuable in assessing fractures that are not well seen in AP, oblique, and lateral views of the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5280=[""].join("\n");
var outline_f5_10_5280=null;
var title_f5_10_5281="Mizolastine: International drug information";
var content_f5_10_5281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mizolastine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Mistaline (FR);",
"     </li>",
"     <li>",
"      Mistamine (BE, CH, GB);",
"     </li>",
"     <li>",
"      Mizollen (BE, CH, DE, DK, FR, GB, IT, NL, SE);",
"     </li>",
"     <li>",
"      Zolim (DE);",
"     </li>",
"     <li>",
"      Zolistam (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine, Low-Sedating",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of allergy such as hay fever, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 10 mg tablet daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 10 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10417 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5281=[""].join("\n");
var outline_f5_10_5281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303435\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979577\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979580\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979576\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821125\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979579\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10417\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10417|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_10_5282="Intussusception Air contrast III";
var content_f5_10_5282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intussusception",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Air contrast enema after successful reduction of the intussusception: post-evaluation film.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5282=[""].join("\n");
var outline_f5_10_5282=null;
var title_f5_10_5283="Perinatal stroke risk";
var content_f5_10_5283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Perinatal stroke risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5283=[""].join("\n");
var outline_f5_10_5283=null;
var title_f5_10_5284="Nitisinone: Pediatric drug information";
var content_f5_10_5284=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitisinone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/43/24244?source=see_link\">",
"    see \"Nitisinone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/51/5940?source=see_link\">",
"    see \"Nitisinone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orfadin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Tyrosinemia Type 1, Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/43/24244?source=see_link\">",
"      see \"Nitisinone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: HT-1:",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in conjunction with a diet restricted in tyrosine and phenylalanine. Infants, Children, and Adults: Initial: 1 mg/kg/day in two divided doses;  adjust dose if inadequate response, as defined by continued abnormal biological parameters (erythrocyte PBG-synthase activity, urine 5-ALA, and urine succinylacetone) despite treatment.  If the aforementioned parameters are not available, may use urine succinylacetone, liver function tests, alpha-fetoprotein, serum tyrosine, and serum phenylalanine to evaluate response (exceptions may include during initiation of therapy and exacerbations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abnormal biological parameters at 1 month: Increase dose to 1.5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abnormal biological parameters at 3 months: Increase to maximum dose of 2 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orfadin&reg;: 2 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Distributed by Rare Disease Therapeutics, Inc; for information regarding acquisition of product, call Accredo Health Group, Inc at 1-888-454-8860",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer in two divided doses in the morning and evening, at least 1 hour prior to, or 2 hours after a meal. The total daily dose does not need to be split evenly; divide the total dose to limit the total number of capsules administered at each interval. Capsules may be opened and contents suspended in a small quantity of water, formula, or applesauce; use immediately.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in refrigerator 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1) (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F201718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dry skin, exfoliative dermatitis, maculopapular rash, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Epistaxis, granulocytopenia, leukopenia, porphyria, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic failure, hepatic neoplasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharitis, cataracts, conjunctivitis, corneal opacity, eye pain, keratitis, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, amenorrhea, brain tumor, bronchitis, corneal ulceration, cyanosis, dehydration, diarrhea, enanthema, encephalopathy, gastritis, gastroenteritis, gastrointestinal hemorrhage, headache, hepatic dysfunction, hepatomegaly, hyperkinesias, hypoglycemia, infection, liver enzymes increased, melena, nervousness, otitis, pathologic fracture, respiratory insufficiency, seizure, septicemia, somnolence, thirst, tooth discoloration, tyrosine levels increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitisinone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Slit-lamp examination of the eyes should be performed prior to initiation of nitisinone therapy; patients who develop photophobia, eye pain or signs of inflammation such as redness, swelling, or burning of the eyes during treatment should be re-examined and a plasma tyrosine concentration measured; if the plasma tyrosine concentration is &gt;500 micromoles/L, a more tyrosine- and phenylalanine-restrictive diet is indicated. Patients with HT-1 are at risk for developing porphyric crises, liver failure, or hepatic neoplasm; regular liver monitoring by imaging (ultrasound, CT scan, MRI), liver function tests, and measurement of serum alpha-fetoprotein concentration is recommended; an increase in serum alpha-fetoprotein or signs of nodules in the liver during treatment may be a sign of inadequate therapy or hepatic malignancy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nitisinone therapy should be initiated by individuals experienced in the management of inborn errors of metabolism including treatment of HT-1. Dietary restriction of tyrosine and phenylalanine must be used in conjunction with nitisinone; inadequate dietary restriction can result in increased plasma tyrosine concentrations leading to toxic ophthalmic effects (corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, and photophobia), skin effects (painful hyperkeratotic plaques on the soles and palms), and variable degrees of mental retardation and developmental delay. Nitisinone dosage should not be adjusted in order to lower the plasma tyrosine concentration. Transient thrombocytopenia and leukopenia has been reported; platelet and WBC counts should be monitored regularly during nitisinone therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dietary tyrosine and phenylalanine intake; platelets, WBC, plasma and urine succinylacetone concentrations, serum alpha-fetoprotein, serum phosphate (if renal dysfunction), hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Function (ultrasound, computerized tomography, magnetic resonance imaging)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic exam (Slit-lamp examination prior to initiation of therapy and in patients who develop symptoms of ocular toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Plasma tyrosine concentrations should be kept &lt;500 &mu;mol/L to avoid toxicity",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1060572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma tyrosine concentration &lt;500 micromoles/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme of the tyrosine metabolic pathway. Hereditary tyrosinemia type 1 (HT-1) occurs due to a deficiency in fumarylacetoacetase (FAH), the final enzyme in the tyrosine metabolic pathway. This deficiency results in an accumulation of maleylacetoacetate and fumarylacetoacetate. These catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate which are responsible for progressive liver failure, increased risk of hepatocellular carcinoma, coagulopathy, painful neurologic crises, and renal tubular dysfunction with rickets. Nitisinone prevents the formation of these toxic metabolites.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Limited pharmacokinetic studies exist in HT-1 patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &gt;90% (animal studies)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 54 hours (healthy volunteers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 3 hours (healthy volunteers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Equal amounts in urine and feces (McKiernan, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/51/5940?source=see_link\">",
"      see \"Nitisinone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Advise patients and caregivers of the need to maintain a diet low in tyrosine and phenylalanine; report eye symptoms, rash, jaundice, or excessive bleeding to a physician promptly",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hall MG, Wilks MF, Provan WM, et al, \"Pharmacokinetics and Pharmacodynamics of NTBC (2-(2-Nitro-4-Fluoromethylbenzoyl)-1,3-Cyclohexanedione) and Mesotrione, Inhibitors of 4-Hydroxyphenyl Pyruvate Dioxygenase (HPPD) Following a Single Dose to Healthy Male Volunteers,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2001, 52(2):169-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/10/5284/abstract-text/11488774/pubmed\" id=\"11488774\" target=\"_blank\">",
"        11488774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holme E and Lindstedt S, &ldquo;Diagnosis and Management of Tyrosinemia Type I,&rdquo;",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 1995, 7(6):726-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/10/5284/abstract-text/8776026 /pubmed\" id=\"8776026 \" target=\"_blank\">",
"        8776026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holme E and Lindstedt S, \"Nontransplant Treatment of Tyrosinemia,\"",
"      <i>",
"       Clin Liver Dis",
"      </i>",
"      , 2000, 4(4):805-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/10/5284/abstract-text/11232358/pubmed\" id=\"11232358\" target=\"_blank\">",
"        11232358",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindstedt S, Holme E, Lock EA, et al, \"Treatment of Hereditary Tyrosinaemia Type I by Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8823):813-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/10/5284/abstract-text/1383656/pubmed\" id=\"1383656\" target=\"_blank\">",
"        1383656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKiernan PJ, \"Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2006, 66(6):743-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/10/5284/abstract-text/16706549/pubmed\" id=\"16706549\" target=\"_blank\">",
"        16706549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12644 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5284=[""].join("\n");
var outline_f5_10_5284=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201700\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060570\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060563\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201683\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201670\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234123\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060574\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060566\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060573\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201718\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060577\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060562\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060561\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299764\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221931\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201678\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060569\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060572\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060560\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060576\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060568\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12644\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12644|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/43/24244?source=related_link\">",
"      Nitisinone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/51/5940?source=related_link\">",
"      Nitisinone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_10_5285="Ultrasound fetal schizencephaly";
var content_f5_10_5285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schizencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 566px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney Stephenson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5285=[""].join("\n");
var outline_f5_10_5285=null;
var title_f5_10_5286="Nephron anatomy PI";
var content_f5_10_5286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Anatomy of the nephron",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 569px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the structure of the nephron, which filters waste from the body's blood supply. Each nephron is composed of a glomerulus and a tubule. The glomerulus filters wastes and excess fluids, while the tubules modify the waste to form urine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5286=[""].join("\n");
var outline_f5_10_5286=null;
var title_f5_10_5287="Williams-Beuren syndrome";
var content_f5_10_5287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Williams-Beuren syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5287/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5287/contributors\">",
"     Wayne R Waz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5287/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5287/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5287/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5287/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/10/5287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17783460\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Williams-Beuren Syndrome (WBS) (also known as Williams syndrome; MIM #194050 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/1\">",
"     1",
"    </a>",
"    ]) is a multisystem genetic disorder caused by hemizygous deletion of 1.5 to 1.8 Mb on chromosome 7q11.23, encompassing about 28 genes including the elastin gene, ELN. Affected patients present with variable phenotypic expression of the following manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;Elfin&rdquo; facies",
"     </li>",
"     <li>",
"      Supravalvular aortic stenosis or other vascular anomalies",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Cognitive profile consisting of impaired cognition and development accompanied by a friendly, social personality",
"     </li>",
"     <li>",
"      Short stature",
"     </li>",
"     <li>",
"      Endocrine abnormalities including hypercalcemia, diabetes mellitus, and subclinical hypothyroidism",
"     </li>",
"     <li>",
"      Genitourinary abnormalities include congenital anomalies of the kidney and urinary tract, nephrolithiasis due to hypercalciuria, and dysfunctional voiding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Auditory, dental, gastrointestinal, genitourinary, musculoskeletal, neurologic, ophthalmologic, and dermatologic abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A summary of the diagnosis and evaluation of WBS, and an in-depth review of the renal manifestations of this disorder are presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17783467\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis is usually made in infancy or early childhood based on recognition of the characteristic features of WBS. Genetic testing is important to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16933956\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2993965\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical diagnosis is most often based on the presence of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysmorphic facial features described as elfin or pixie-like, which consist of a broad forehead, medial eyebrow flare, strabismus, flat nasal bridge, malar flattening, a short nose with a long philtrum, full lips, and a wide mouth [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/2,4,5\">",
"       2,4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      About one-fourth of children with supravalvular aortic stenosis will have WBS. Other cardiovascular anomalies associated with WBS include pulmonary artery stenosis and, less often, stenosis of other mid-size arteries such as renal arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/6-9\">",
"       6-9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=see_link&amp;anchor=H5#H5\">",
"       \"Supravalvar aortic stenosis\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mild to moderate developmental delay with a characteristic cognitive and behavior profile [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients with WBS generally have global cognitive impairment with a higher average verbal intelligent quotient (IQ) then performance IQ. They also display a relative strength in auditory rote memory and specific aspects of language, and weakness in visuospatial and visuomotor skills. Affected individuals are friendly and social, and they are often described as having a &ldquo;cocktail party&rdquo; personality.",
"     </li>",
"     <li>",
"      Although not as common a presentation, WBS may present as idiopathic hypercalcemia and hypercalciuria [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16933956\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of a clinical diagnosis is made with chromosomal analysis that demonstrates the deletion at 7q.11.23. The genetic defect is detected by fluorescence in situ hybridization (FISH) with probes specific for the elastin gene, one of approximately 26 to 28 genes located at 7q11.23 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ]. Chromosomal microarray analysis (also called comparative genomic hybridization) is also clinically available to make the genetic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/12\">",
"     12",
"    </a>",
"    ]. The use of genetic testing to confirm the diagnosis has demonstrated that this disorder is one of the more common genetic disorders with an estimated incidence of 1:10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Hemizygosity for elastin is responsible for the vascular and valvular abnormalities of WBS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/2\">",
"     2",
"    </a>",
"    ]. Haploinsufficiency of adjacent genes, such as the LIMK1 gene, probably accounts for the other manifestations of this disorder, including the impaired visuospatial constructive cognition and developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17783474\">",
"    <span class=\"h1\">",
"     HEALTH CARE SUPERVISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of WBS has been made and confirmed by genetic testing, initial evaluation and ongoing surveillance are focused on determining whether the affected patient has or will subsequently develop any significant complication associated with this genetic disorder.",
"   </p>",
"   <p>",
"    As noted above, patients with WBS are at risk for [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Supravalvular aortic stenosis or other vascular anomalies",
"     </li>",
"     <li>",
"      Hypertension (See",
"      <a class=\"local\" href=\"#H17783481\">",
"       'Hypertension'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Developmental and cognitive impairment",
"     </li>",
"     <li>",
"      Short stature",
"     </li>",
"     <li>",
"      Endocrine abnormalities including hypercalcemia, diabetes mellitus, and subclinical hypothyroidism (See",
"      <a class=\"local\" href=\"#H17783488\">",
"       'Hypercalcemia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Genitourinary abnormalities including congenital anomalies of the kidney and urinary tract (CAKUT), nephrocalcinosis due to hypercalciuria, and dysfunctional voiding (See",
"      <a class=\"local\" href=\"#H17783495\">",
"       'Renal and urinary tract abnormalities'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Auditory, dental, gastrointestinal, musculoskeletal, neurologic, and ophthalmologic abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H496569806\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2001 American Academy of Pediatrics (AAP) health care supervision guidelines for WBS, the initial recommended evaluation includes the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete physical examination including neurologic assessment and growth measurements. Weight, height, and head circumference should be plotted on growth charts specifically developed for patients with WBS.",
"     </li>",
"     <li>",
"      Blood pressure (BP) measurement in all four extremities.",
"     </li>",
"     <li>",
"      Cardiology evaluation including echocardiography.",
"     </li>",
"     <li>",
"      Genitourinary evaluation including renal function studies (ie, serum urea nitrogen and creatinine), renal ultrasonography, and urinalysis.",
"     </li>",
"     <li>",
"      Audiologic testing at 6 to 12 months because of associated high-tone sensorineural hearing loss. In addition, recurrent otitis media is common in patients with WBS.",
"     </li>",
"     <li>",
"      Additional laboratory evaluation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum calcium, and urinary calcium and creatinine measurements",
"     </li>",
"     <li>",
"      Thyroid function studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H496569717\">",
"    <span class=\"h2\">",
"     Continued care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the risk of progressive disease, ongoing assessment is recommended throughout the lifetime of the affected individual [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/3\">",
"     3",
"    </a>",
"    ]. Routine medical monitoring will detect complications that may require referral to a pediatric nephrologist or cardiologist. As an example, common renal manifestations that may require referral include hypertension, hypercalcemia and nephrocalcinosis, and renal and urologic abnormalities.",
"   </p>",
"   <p>",
"    The 2001 AAP guideline for the care of children with WBS outlines a series of evaluation based on patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/3\">",
"     3",
"    </a>",
"    ]. For each age group, annual evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physical examination with assessment of growth and BP measurements",
"     </li>",
"     <li>",
"      Developmental assessment",
"     </li>",
"     <li>",
"      Auditory and vision screening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular evaluation &mdash; In particular, progressive vascular stenosis may occur including supravalvar aortic stenosis, which is generally seen in the first three to five years of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=see_link\">",
"       \"Supravalvar aortic stenosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other additional key components are based on the age of the patient and the results of previous testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age 1 to 5 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Laboratory evaluation &mdash; Annual urinalysis and annual measurement of serum calcium if elevated at initial evaluation or if symptomatic; otherwise, serum calcium is measured every two to three years. Measurement of spot urine calcium-to-creatinine ratio every two years, and serum creatinine and thyroid function studies every four years.",
"     </li>",
"     <li>",
"      Assess for feeding issues (eg, constipation and rectal prolapse).",
"     </li>",
"     <li>",
"      Assess for orthopedic and neurologic abnormalities (eg, spasticity, hypotonia, and joint laxity and contractures).",
"     </li>",
"     <li>",
"      An ophthalmologic evaluation before three years of age to detect strabismus, amblyopia, and refractive errors. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age 5 to 12 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Laboratory evaluation &mdash; Annual urinalysis and annual measurement of serum calcium if elevated at initial evaluation or if symptomatic; otherwise, serum calcium is measured every four years. Measurement of spot urine calcium-to-creatinine ratio every two years, serum creatinine every two to four years, and thyroid function studies every four years.",
"     </li>",
"     <li>",
"      Assess for neurologic and orthopedic abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age 13 to 18 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The history and physical examination should include assessing for progressive medical issues that begin to occur in adolescent and young adult patients. This includes hypertension, progressive joint limitations, recurrent urinary tract infections, development of diabetes mellitus, sensorineural hearing loss, and gastrointestinal issues (eg, diverticulitis and diverticulosis, cholelithiasis, and chronic constipation).",
"     </li>",
"     <li>",
"      Laboratory evaluation &mdash; Annual urinalysis; spot urine calcium-to-creatinine measurement every two years; serum creatinine ratio every two to four years; serum calcium if there are symptoms suggestive of hypercalcemia, otherwise every four years; and thyroid function studies every four years.",
"     </li>",
"     <li>",
"      Bladder and renal ultrasonography at puberty and every five years thereafter. Renal ultrasound is useful to screen for nephrocalcinosis or nephrolithiasis in patients with a previous history of hypercalcemia, and may detect kidney size discrepancy that may be associated with significant renal artery stenosis. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiovascular complications are the major cause of death in these patients. In particular, unexpected cardiac deaths have been associated with the administration of general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As a result, the 2001 AAP guidelines recommend that a pediatric anesthesiologist be consulted for any child with WBS who requires anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17783481\">",
"    <span class=\"h1\">",
"     HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, which may begin in childhood, typically develops in almost half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a small case series of 20 patients, 24-hour ambulatory blood pressure monitoring detected hypertension in 40 percent of adults (compared with 14 percent of controls) and 46 percent of children (compared with 6 percent of controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although supravalvular aortic stenosis and pulmonary artery stenosis are the most common vascular anomalies noted in WBS, renal artery stenosis and stenotic anomalies of the abdominal aorta also occur, which result in renovascular hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ]. In some cases, no renovascular cause for the hypertension is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. In a series of 41 children with WBS, renal artery stenosis was the cause of hypertension in only 58 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/12\">",
"     12",
"    </a>",
"    ]. It is speculated that elevated BP in these patients without renal artery stenosis is a reflection of a physiological adaptation to abnormal vasculature even in the absence of renal artery or abdominal aorta stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/19\">",
"     19",
"    </a>",
"    ]. The arteriopathy is due to proliferation of vascular smooth muscle cell and increased media-to-intima thickness that are caused by defects in the elastin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of hypertension in a patient with WBS should prompt a search for discrete vascular lesions. Initial evaluation is similar to that recommended for all patients with pediatric hypertension that may be due to secondary causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of hypertension in children and adolescents\", section on 'Initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiogram to detect the presence or absence of left ventricular hypertrophy.",
"     </li>",
"     <li>",
"      Renal with Doppler flow studies of the renal arteries and abdominal aorta because of the increased likelihood that renal artery stenosis is causing the elevation in BP.",
"     </li>",
"     <li>",
"      Urinalysis, and measurement of serum electrolytes, BUN, and creatinine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with suspicious or inconclusive studies should be referred to a clinician with expertise in evaluating pediatric renovascular hypertension (eg, pediatric cardiologist, nephrologist, interventional radiologist, or vascular surgeon) who can assess the relative merits of pharmacologic or interventional therapies, such as renal angiography. However, the results of surgical repair or percutaneous transluminal angioplasty are poor with either persistent hypertension or recurrence of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. As a result, some experts, including the author, recommend an initial trial of antihypertensive medications and reserve evaluation for renovascular causes for those patients resistant to pharmacologic therapy",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/7,20\">",
"     7,20",
"    </a>",
"    ] because a specific lesion is often not found and may not be responsive to subsequent interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. However, other experts in the field would evaluate all patients with hypertension for an underlying renovascular etiology.",
"   </p>",
"   <p>",
"    In patients with WBS, effective control of hypertension has been reported with calcium channel blockers and beta blockers. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers may also be effective but should be used with caution if there is any suspicion of middle aortic syndrome or bilateral renal artery stenosis.",
"   </p>",
"   <p>",
"    In our practice, we begin therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/22/36199?source=see_link\">",
"     amlodipine",
"    </a>",
"    , a calcium channel blocker, in patients whose initial work-up for HTN is negative or inconclusive. Further evaluation is generally indicated for patients who are refractory to pharmacologic therapy.",
"   </p>",
"   <p>",
"    Arteriography, an invasive procedure, is the gold standard to diagnose renovascular hypertension and is performed in patients with refractory hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation of hypertension in children and adolescents\", section on 'Renovascular imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17783488\">",
"    <span class=\"h1\">",
"     HYPERCALCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with WBS have higher serum calcium concentration than the general pediatric population.",
"   </p>",
"   <p>",
"    Hypercalcemia is usually mild to moderate and not typically symptomatic. In some cases, episodes of hypercalcemia may present with irritability, hypotonia, decreased appetite, or constipation. Hypercalciuria is often found during episodes of hypercalcemia and infrequently results in nephrocalcinosis, which is detected in about 5 to 10 percent of patients undergoing renal ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/10,17,23-25\">",
"     10,17,23-25",
"    </a>",
"    ]. Hypercalciuria is not common after the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of the increased risk of hypercalcemia is unknown. The following mechanisms have been proposed but none have been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated 1,25 dihydroxyvitamin D levels [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased vitamin D sensitivity",
"     </li>",
"     <li>",
"      Defective calcitonin synthesis and release [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No evidence-based recommendations for treatment have been published. Some experts in the field recommend treatment of hypercalcemia with a low calcium diet and vitamin D restriction, but in one case report, this therapy resulted in the development of rickets in an infant [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/28\">",
"     28",
"    </a>",
"    ]. As a result, this therapeutic approach is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in infants and young children. Effective use of bisphosphonates has been reported in a single case report [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/29\">",
"     29",
"    </a>",
"    ]. Vitamin D supplementation including multivitamins should be avoided in children with WBS, and sunscreen should be used to minimize the autologous production of vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17783495\">",
"    <span class=\"h1\">",
"     RENAL AND URINARY TRACT ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of kidney and urinary tract abnormalities ranges from 18 to 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In several case series, renal ultrasonography has demonstrated a wide spectrum of structural abnormalities from bladder diverticula, ectopic or horseshoe kidney to renal aplasia or hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/17,21,24,25\">",
"     17,21,24,25",
"    </a>",
"    ]. Based on these findings, a renal ultrasound should be performed as part of the initial evaluation when the diagnosis of WBS has been made [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H496569806\">",
"     'Initial evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Decreased renal function has been noted in a small number of patients, but there is no reported follow-up regarding progression of chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. Serum creatinine levels should be routinely monitored; the frequency of testing is dependent upon whether there is evidence of renal impairment. In particular, patients with hypoplastic or dysplastic kidneys should be followed for the progression of chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Natural history and progression of chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with WBS also may present with recurrent urinary tract infection, vesicoureteral reflux,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysfunctional voiding. Case series from a Brazilian tertiary center report that the majority of patients with WBS have symptoms of dysfunctional voiding (eg, increased urinary frequency, enuresis, and urgency) and abnormal urodynamic findings including detrusor overactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5287/abstract/21,30\">",
"     21,30",
"    </a>",
"    ]. These findings suggest that a voiding history should be included in the evaluation of patients with WBS. Further diagnostic evaluation including voiding cystourethrogram,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urodynamic studies should be considered in symptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=see_link\">",
"     \"Etiology and clinical features of bladder dysfunction in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In older patients who develop diabetes mellitus, screening for microalbuminuria and hypertension is recommended because of the risk of diabetic nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17783814\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Patrick Niaudet, who contributed to an earlier version of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588881124\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Williams-Beuren Syndrome (WBS) (also known as Williams syndrome; MIM #194050) is a multisystem genetic disorder caused by hemizygous deletion of 1.5 to 1.8 Mb on chromosome 7q11.23.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Affected patients present with variable expression of the following associated characteristics (see",
"      <a class=\"local\" href=\"#H17783467\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17783474\">",
"       'Health care supervision'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &ldquo;Elfin&rdquo; facies",
"     </li>",
"     <li>",
"      Supravalvular aortic stenosis or other vascular anomalies",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Cognitive profile consisting of impaired cognition and development accompanied by a friendly, social personality",
"     </li>",
"     <li>",
"      Short stature",
"     </li>",
"     <li>",
"      Endocrine abnormalities including hypercalcemia, diabetes mellitus, and subclinical hypothyroidism",
"     </li>",
"     <li>",
"      Genitourinary abnormalities include congenital anomalies of the kidney and urinary tract, nephrolithiasis due to hypercalciuria, and dysfunctional voiding",
"     </li>",
"     <li>",
"      Auditory, dental, gastrointestinal, genitourinary, musculoskeletal, neurologic, and ophthalmologic abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinical diagnosis is usually made in infancy or early childhood based on recognition of the characteristic features of WBS. Genetic testing demonstrating the presence of a single ELN allele confirms the diagnosis. (See",
"      <a class=\"local\" href=\"#H17783467\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of WBS has been confirmed by genetic testing, further evaluation is performed to detect any of the significant clinical findings of this disorder. In 2001, the American Academy of Pediatrics (AAP) published health care supervision that outlined the following initial evaluation for patients diagnosed with WBS. (See",
"      <a class=\"local\" href=\"#H496569806\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete physical examination including neurologic assessment and growth measurements. Growth measurements plotted on growth charts for patients with WBS.",
"     </li>",
"     <li>",
"      Blood pressure (BP) measurements in all four extremities.",
"     </li>",
"     <li>",
"      Cardiology evaluation including echocardiography.",
"     </li>",
"     <li>",
"      Genitourinary evaluation including renal function studies (ie, serum urea nitrogen and creatinine), renal ultrasonography, and urinalysis.",
"     </li>",
"     <li>",
"      Audiologic testing at 6 to 12 months.",
"     </li>",
"     <li>",
"      Other laboratory testing includes serum calcium, urinary calcium and creatinine, and thyroid function studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because there is a risk of developing associated complications during the natural course of this disorder, ongoing routine assessment should be performed. The 2001 AAP guidelines include a series of evaluations based on patient age for continued health supervision for children with WBS. For each age group, annual evaluation includes physical examination with assessment of growth and BP measurements, developmental assessment, cardiovascular evaluation, and annual hearing and vision screening. Additional screening and testing are dependent on the age of the patient and the results of previous testing. (See",
"      <a class=\"local\" href=\"#H496569717\">",
"       'Continued care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypertension typically develops in almost half of patients with WBS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that pediatric patients with WBS and hypertension be evaluated according to general pediatric guidelines.",
"     </li>",
"     <li>",
"      In patients with a negative initial work-up, we suggest antihypertensive therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Antihypertensive agents include calcium channel blockers (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/22/36199?source=see_link\">",
"       amlodipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"       nifedipine",
"      </a>",
"      ), ACE inhibitors (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"       enalapril",
"      </a>",
"      ), or beta-blockers (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"       labetalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"       atenolol",
"      </a>",
"      ). In our practice, we generally use amlodipine, a calcium channel blocker.",
"     </li>",
"     <li>",
"      ACE inhibitors should not be used in any patients whose initial screen reveals possible bilateral renal artery disease or underlying renal disease.",
"     </li>",
"     <li>",
"      More extensive evaluation for renovascular causes is generally reserved for those patients resistant to pharmacologic treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17783481\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercalcemia is a common manifestation of WBS and is usually mild and asymptomatic. In some cases, symptomatic hypercalcemia may present with irritability, hypotonia, decreased appetite, or constipation. Hypercalciuria is often found during episodes of hypercalcemia, which may result in nephrocalcinosis. There are no known effective and safe treatments for hypercalcemia in patients with WBS. Vitamin D supplementation including multivitamins should be avoided in children with WBS, and sunscreen should be used to minimize the autologous production of vitamin D. (See",
"      <a class=\"local\" href=\"#H17783488\">",
"       'Hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal and urinary tract abnormalities are common in patients with WBS. Structural anomalies range from bladder diverticula, ectopic or horseshoe kidney to renal aplasia or hypoplasia. Recurrent urinary tract infections, vesicoureteral reflux, and dysfunctional voiding are also abnormalities frequently observed in this disorder. Decreased renal function is an uncommon but serious complication. (See",
"      <a class=\"local\" href=\"#H17783495\">",
"       'Renal and urinary tract abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Center for Biotechnology Information, Online Mendelian Inheritance in Man. Williams-Beuren Syndrome (WBS) MIM #194050. file://www.ncbi.nlm.nih.gov/omim/194050.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/2\">",
"      Pober BR. Williams-Beuren syndrome. N Engl J Med 2010; 362:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/3\">",
"      Committee on Genetics. American Academy of Pediatrics: Health care supervision for children with Williams syndrome. Pediatrics 2001; 107:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/4\">",
"      Jones KL, Smith DW. The Williams elfin facies syndrome. A new perspective. J Pediatr 1975; 86:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/5\">",
"      Morris CA, Demsey SA, Leonard CO, et al. Natural history of Williams syndrome: physical characteristics. J Pediatr 1988; 113:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/6\">",
"      Ino T, Nishimoto K, Iwahara M, et al. Progressive vascular lesions in Williams syndrome. J Pediatr 1985; 107:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/7\">",
"      Pober BR, Johnson M, Urban Z. Mechanisms and treatment of cardiovascular disease in Williams-Beuren syndrome. J Clin Invest 2008; 118:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/8\">",
"      Radford DJ, Pohlner PG. The middle aortic syndrome: an important feature of Williams' syndrome. Cardiol Young 2000; 10:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/9\">",
"      Sugayama SM, Mois&eacute;s RL, Wag&euml;nfur J, et al. Williams-Beuren syndrome: cardiovascular abnormalities in 20 patients diagnosed with fluorescence in situ hybridization. Arq Bras Cardiol 2003; 81:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/10\">",
"      Sforzini C, Milani D, Fossali E, et al. Renal tract ultrasonography and calcium homeostasis in Williams-Beuren syndrome. Pediatr Nephrol 2002; 17:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/11\">",
"      Lowery MC, Morris CA, Ewart A, et al. Strong correlation of elastin deletions, detected by FISH, with Williams syndrome: evaluation of 235 patients. Am J Hum Genet 1995; 57:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/12\">",
"      Waxler JL, Levine K, Pober BR. Williams syndrome: a multidisciplinary approach to care. Pediatr Ann 2009; 38:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/13\">",
"      Frangiskakis JM, Ewart AK, Morris CA, et al. LIM-kinase1 hemizygosity implicated in impaired visuospatial constructive cognition. Cell 1996; 86:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/14\">",
"      Burch TM, McGowan FX Jr, Kussman BD, et al. Congenital supravalvular aortic stenosis and sudden death associated with anesthesia: what's the mystery? Anesth Analg 2008; 107:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/15\">",
"      Bird LM, Billman GF, Lacro RV, et al. Sudden death in Williams syndrome: report of ten cases. J Pediatr 1996; 129:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/16\">",
"      Broder K, Reinhardt E, Ahern J, et al. Elevated ambulatory blood pressure in 20 subjects with Williams syndrome. Am J Med Genet 1999; 83:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/17\">",
"      Ingelfinger JR, Newburger JW. Spectrum of renal anomalies in patients with Williams syndrome. J Pediatr 1991; 119:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/18\">",
"      Rose C, Wessel A, Pankau R, et al. Anomalies of the abdominal aorta in Williams-Beuren syndrome--another cause of arterial hypertension. Eur J Pediatr 2001; 160:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/19\">",
"      Faury G, Pezet M, Knutsen RH, et al. Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency. J Clin Invest 2003; 112:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/20\">",
"      Bouchireb K, Boyer O, Bonnet D, et al. Clinical features and management of arterial hypertension in children with Williams-Beuren syndrome. Nephrol Dial Transplant 2010; 25:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/21\">",
"      Sugayama SM, Koch VH, Furusawa EA, et al. Renal and urinary findings in 20 patients with Williams-Beuren syndrome diagnosed by fluorescence in situ hybridization (FISH). Rev Hosp Clin Fac Med Sao Paulo 2004; 59:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/22\">",
"      Courtel JV, Soto B, Niaudet P, et al. Percutaneous transluminal angioplasty of renal artery stenosis in children. Pediatr Radiol 1998; 28:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/23\">",
"      Cote G, Jequier S, Kaplan P. Increased renal medullary echogenicity in patients with Williams syndrome. Pediatr Radiol 1989; 19:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/24\">",
"      Pankau R, Partsch CJ, Winter M, et al. Incidence and spectrum of renal abnormalities in Williams-Beuren syndrome. Am J Med Genet 1996; 63:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/25\">",
"      Pober BR, Lacro RV, Rice C, et al. Renal findings in 40 individuals with Williams syndrome. Am J Med Genet 1993; 46:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/26\">",
"      Garab&eacute;dian M, Jacqz E, Guillozo H, et al. Elevated plasma 1,25-dihydroxyvitamin D concentrations in infants with hypercalcemia and an elfin facies. N Engl J Med 1985; 312:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/27\">",
"      Culler FL, Jones KL, Deftos LJ. Imparied calcitonin secretion in patients with Williams syndrome. J Pediatr 1985; 107:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/28\">",
"      Mathias RS. Rickets in an infant with Williams syndrome. Pediatr Nephrol 2000; 14:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/29\">",
"      Oliveri B, Mastaglia SR, Mautalen C, et al. Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate). Acta Paediatr 2004; 93:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5287/abstract/30\">",
"      Sammour ZM, Gomes CM, Duarte RJ, et al. Voiding dysfunction and the Williams-Beuren syndrome: a clinical and urodynamic investigation. J Urol 2006; 175:1472.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6127 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5287=[""].join("\n");
var outline_f5_10_5287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H588881124\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17783460\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17783467\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2993965\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16933956\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17783474\">",
"      HEALTH CARE SUPERVISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H496569806\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H496569717\">",
"      Continued care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17783481\">",
"      HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17783488\">",
"      HYPERCALCEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17783495\">",
"      RENAL AND URINARY TRACT ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17783814\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H588881124\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=related_link\">",
"      Epidemiology, etiology, and course of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=related_link\">",
"      Etiology and clinical features of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=related_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40774?source=related_link\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_10_5288="Low grade muc cys neo";
var content_f5_10_5288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histologic appearance of mucinous cystic neoplasm, low grade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-grade mucinous cystic neoplasm of the pancreas The cellular (ovarian) stroma lies immediately below the mucinous epithelium lining the cyst, and a dense collagenous capsule is visible at the bottom of the field. Hematoxylin and eosin-stained section.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel S Longnecker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5288=[""].join("\n");
var outline_f5_10_5288=null;
var title_f5_10_5289="Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis";
var content_f5_10_5289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5289/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5289/contributors\">",
"     Liza Bonin, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5289/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5289/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5289/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5289/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/10/5289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 3, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several myths characterize the literature on depression in youth. As an example, early psychoanalytic formulations presumed that children and young adolescents did not have the psychological structure (eg, superego functions) to truly experience depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Clinical and empirical evidence reveal that children and adolescents do indeed suffer from both depressive symptoms and depressive disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, some authors conceptualized depression as evident in youth with the essential features (eg, dysphoric mood, loss of interest) typically absent. They believed that these features were either \"masked\" or expressed in depressive equivalents such as somatic complaints, disruptive behavior, or school problems [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/5\">",
"     5",
"    </a>",
"    ]. In fact, depression in children and adolescents was overlooked rather than \"masked\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/6\">",
"     6",
"    </a>",
"    ], possibly because disruptive behaviors and comorbid disorders were more salient than were depressive symptoms.",
"   </p>",
"   <p>",
"    In addition, the classic characterization of adolescence as a time of \"storm and stress\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/7\">",
"     7",
"    </a>",
"    ] led many researchers to view depression during adolescence as a normal developmental stage. In fact, most youth progress through adolescence without undue emotional turbulence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]; only 20 percent experience psychologic disturbance, a figure comparable to the rate in adults. However, adolescence is a critical period for the development of depressive disorders.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and diagnosis of depression in adolescents are reviewed here. The treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=see_link\">",
"     \"Overview of treatment for adolescent depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link\">",
"     \"Psychopharmacological treatment for adolescent depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=see_link\">",
"     \"Psychosocial treatment for adolescent depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for depression increases in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/3\">",
"     3",
"    </a>",
"    ]. Whereas the point prevalence of major depressive disorder (MDD) in children is approximately 2 percent, in adolescents it is estimated to be 4 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Similarly, the few studies on dysthymic disorder (DD) report a point prevalence from 0.6 to 1.7 percent in children and 1.6 to 8 percent in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/12\">",
"     12",
"    </a>",
"    ]. The cumulative incidence of MDD during adolescence is estimated to range from 15 to 20 percent, a rate comparable to the lifetime prevalence of MDD found in adult populations. Investigators interpret these data as suggesting that depression in adults has its roots in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/6,13,14\">",
"     6,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult women are approximately twice as likely to be depressed as adult men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/15\">",
"     15",
"    </a>",
"    ]. Similarly, teenage girls are at greater risk for developing depression during adolescence than are teenage boys. In childhood, the rate of MDD is comparable in boys and girls, whereas in adolescence the female-to-male ratio approaches 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The gender difference emerges in early adolescence and persists throughout adulthood, further supporting the view that depression in adults has its origins in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historical factors that place adolescents at increased risk for depression include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/4,10,19-28\">",
"     4,10,19-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of depression in first-degree relatives",
"     </li>",
"     <li>",
"      Prior depressive episodes",
"     </li>",
"     <li>",
"      History of anxiety disorders, attention deficit hyperactivity disorder, learning disabilities, and early losses",
"     </li>",
"     <li>",
"      Family dysfunction or caregiver-child conflict",
"     </li>",
"     <li>",
"      Peer problems",
"     </li>",
"     <li>",
"      Academic difficulties",
"     </li>",
"     <li>",
"      Negative style of interpreting events and coping with stress",
"     </li>",
"     <li>",
"      Chronic illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adolescents with a genetic predisposition to depression are at considerably increased risk when faced with the expected, although difficult, transitions of adolescence or when faced with unexpected psychosocial stressors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Adolescents are more at risk for developing depression than they were in the past. Compared with those born earlier, individuals born in the latter part of the 20th century are at greater risk for mild or moderate mood disorders and manifest the disorders at a younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/16,31-33\">",
"     16,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical course of a major depressive episode in adolescence is seven to nine months; 90 percent of adolescent depressions remit within two years. Relapse is common; cumulative probability of recurrence is 40 percent by two years and 70 percent by five years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMPACT OF DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sadness and irritability are a normal, adaptive part of the human condition, particularly in response to loss, disappointment, or perceived failure. Accordingly, transient mood changes or loss of interest in normally pleasurable activities do not represent psychiatric impairment. For mood changes to qualify as a psychiatric disorder, they must persist and cause significant distress or interfere with a person's basic functioning.",
"   </p>",
"   <p>",
"    Common functional impairments in adolescents include disturbances in school functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/34\">",
"     34",
"    </a>",
"    ], relationships with parents and peers, and initiative and involvement in daily activities and responsibilities. In addition to the psychosocial impairments, depressed adolescents are more likely to manifest health problems and report somatic complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Of additional concern, depressed adolescents are at increased risk for engaging in high-risk behaviors such as promiscuity, smoking, abuse of alcohol and other substances, and suicide attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The academic and social sequelae of depression during adolescence, a time when most teens strive to define themselves and establish a social role outside the family, increase the risk for future depressive episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/39\">",
"     39",
"    </a>",
"    ]. Examples of depressive sequelae that perpetuate depression include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interpersonal dysfunction",
"     </li>",
"     <li>",
"      Social withdrawal",
"     </li>",
"     <li>",
"      Negative attributions about the perceptions or intent of others",
"     </li>",
"     <li>",
"      Excessive seeking of reassurance",
"     </li>",
"     <li>",
"      Academic failure and school avoidance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbidity is the rule rather than the exception for adolescents with depression. Between 40 to 70 percent of depressed children and adolescents have comorbid psychiatric disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/42-44\">",
"     42-44",
"    </a>",
"    ], and at least 20 to 50 percent have two or more comorbid diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequent comorbidities include substance abuse, anxiety disorders, physical or sexual abuse, trauma, and disruptive behavior disorders (eg, ADHD, oppositional defiant disorder, and conduct disorder) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/28\">",
"     28",
"    </a>",
"    ]. Adolescents struggling with depression also are at increased risk for eating disorders, learning disorders, and somatization disorders. Depression in adolescents usually emerges after the comorbid disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/45\">",
"     45",
"    </a>",
"    ], with the exception of substance abuse and conduct problems that develop as a complication of the depression and may persist after the depressive episode remits [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical consequences of comorbidity are of considerable concern. Comorbidity affects functional outcomes, increasing the level of associated social problems, academic problems, and global role impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Furthermore, comorbidity has a deleterious impact on the duration of depressive symptoms, response to treatment, and recurrence of depressive episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/3,50\">",
"     3,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressive disorders are classified as major depressive disorder (MDD), dysthymic disorder (DD), or depressive disorder not otherwise specified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Major depressive disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDD is characterized by a history of one or more major depressive episodes in the absence of manic, hypomanic, or mixed episodes of mood disturbance. To meet DSM-IV criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/51\">",
"     51",
"    </a>",
"    ], the adolescent must display at least five depressive symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depressed or irritable mood",
"     </li>",
"     <li>",
"      Markedly diminished interest or pleasure in almost all activities",
"     </li>",
"     <li>",
"      Change in appetite or weight",
"     </li>",
"     <li>",
"      Insomnia or hypersomnia",
"     </li>",
"     <li>",
"      Psychomotor agitation or retardation",
"     </li>",
"     <li>",
"      Fatigue or loss of energy",
"     </li>",
"     <li>",
"      Feelings of worthlessness or guilt",
"     </li>",
"     <li>",
"      Impaired concentration, indecisiveness",
"     </li>",
"     <li>",
"      Recurring thoughts of death or suicide",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the symptoms must be either depressed (or irritable) mood or loss of interest or pleasure that is present for most of the day, nearly every day, for at least two weeks, with the remaining symptoms present during the same period. The symptoms must cause clinically significant distress or impairment and represent a change from previous functioning. They must not be caused by the direct effects of a substance (eg, drug abuse or medications) or a medical condition (eg, hypothyroidism), and they must not be better accounted for by bereavement. A history of a prior manic episode in addition to these criteria suggests the diagnosis of bipolar disorder.",
"   </p>",
"   <p>",
"    The clinical presentation of childhood and adolescent depressive disorder parallels the phenomenology of depressive disorder in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/52\">",
"     52",
"    </a>",
"    ]. However, some developmental differences exist, and informed clinical judgment often is needed to translate an adolescent's manifestation of symptoms into DSM-IV criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Phenomenology",
"    </span>",
"    &nbsp;&mdash;&nbsp;To clarify the phenomenology of depression in adolescents, each criterion for a major depressive episode is reviewed below with a focus on typical adolescent manifestations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depressed or irritable mood &mdash; Many adolescents directly report a depressed mood, such as feeling down, sad, or blue much of the time. However, depression in adolescents commonly expresses itself primarily as an irritable mood. The DSM-IV provides the \"irritability\" criterion only for children and adolescents because many adolescents and most children lack the emotional and cognitive sophistication to correctly identify and organize their emotional experiences [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/39\">",
"       39",
"      </a>",
"      ]. Irritability, as an example, often manifests in the adolescent's being \"annoyed\" or \"bothered\" by everything and everyone. Rather than expressing sadness, the depressed adolescent may be moody, negative, and argumentative, picking fights as a means to convey his or her emotional distress. He or she often is unable to tolerate frustration and responds to minor provocations with angry outbursts.",
"      <br/>",
"      <br/>",
"      Caregivers of adolescents must listen closely to adolescents to identify a depressed mood, particularly the adolescents' descriptions of how they think about themselves, their world, and their futures [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/53\">",
"       53",
"      </a>",
"      ]. Depressed mood in adolescents may manifest as: finding others antagonistic or uncaring, brooding about real or potentially unpleasant circumstances, a gloomy or hopeless outlook, belief that everything is \"unfair\", or feelings that they disappoint parents or teachers.",
"      <br/>",
"      <br/>",
"      Mood reactivity, the capacity to be cheered up when presented with positive events, is common in adolescents and a characteristic feature of depression with atypical features. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Features'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Mood reactivity can cause adolescents to seek activities and experiences to temporarily lift their moods. Examples of these activities include affiliation with peers, thrill-seeking, promiscuity [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/54\">",
"       54",
"      </a>",
"      ], and drug use. The use of peer affiliation to alleviate depression is differentiated from the normal adolescent need for peer affiliation by its urgency and drive. For the teens who use sexual activity in the same way, a decrease in sexual interest can be a healthful sign of increased emotional stability and appropriate boundaries.",
"     </li>",
"     <li>",
"      Diminished interest or pleasure &mdash; Anhedonia is the psychiatric term referring to the inability to experience pleasure in formerly enjoyable activities. Adolescents with anhedonia experience events, hobbies, interests, and people as less interesting or fun than they used to be. Adolescents express anhedonia by describing experiences as \"boring,\" \"stupid,\" or \"uninteresting.\" They may withdraw from or lose interest in friends. If they are sexually active, they may have decreased libido or interest in sex.",
"     </li>",
"     <li>",
"      Change in appetite or weight &mdash; Change in appetite and corresponding weight loss or gain is characteristic of depression. However, appetite change may not be manifest as often in depressed youngsters as in depressed adults [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/55\">",
"       55",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The failure to make expected weight gains satisfies this criterion for adolescents. Anorexia is more prevalent in adolescent girls than boys. Preoccupation with weight and body image are signs of anorexia nervosa [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/10,56\">",
"       10,56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .) Alternatively, some adolescents with depressive disorders crave and eat more specific foods (eg, junk food and carbohydrates) and accordingly gain more weight than expected during their adolescent growth spurt.",
"     </li>",
"     <li>",
"      Sleep disturbance &mdash; Sleep disturbance is common in depressed adolescents, many of whom describe their sleep as nonrestorative and report difficulty getting out of bed in the morning. Sleep disturbance manifests as insomnia, hypersomnia, or significant shifts of sleep pattern over the diurnal cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/51,55\">",
"       51,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initial insomnia &mdash; difficulty getting to sleep",
"     </li>",
"     <li>",
"      Middle insomnia &mdash; waking in the middle of the night",
"     </li>",
"     <li>",
"      Terminal insomnia &mdash; waking too early in the morning",
"     </li>",
"     <li>",
"      Hypersomnia &mdash; extended nighttime sleep or daytime napping",
"     </li>",
"     <li>",
"      Circadian reversal &mdash; daytime sleeping and nighttime arousal.",
"     </li>",
"     <li>",
"      Psychomotor agitation or retardation &mdash; Psychomotor retardation is common in depressed youth [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/51\">",
"       51",
"      </a>",
"      ]. Adolescents with psychomotor retardation talk or move more slowly than is typical for them. They produce less speech and present with longer response latencies. This criterion is met only if the adolescent actually appears to be moving in slow motion; the subjective experience of feeling slowed down does not qualify.",
"      <br/>",
"      <br/>",
"      Alternatively, some depressed adolescents present with agitation: trouble sitting still, pacing, hand wringing, pulling at or rubbing clothes, tantrums, yelling, shouting, and non-stop talking. Adolescents can have alternating periods of retardation and agitation within a single episode of depression.",
"     </li>",
"     <li>",
"      Fatigue or loss of energy &mdash; This criterion is met if the adolescent reports feeling chronically tired, exhausted, listless, and without energy or motivation. They may feel the need to rest during the day, experience heaviness in their limbs, or feel like it is hard to get going much of the time. Parent-adolescent conflict can result if the parents misinterpret the depressed adolescent's lack of energy and motivation as laziness, an oppositional attitude, or avoidance of responsibilities. Alternatively, parents may be concerned that the adolescent is medically ill and seek a medical explanation for the chronic fatigue.",
"     </li>",
"     <li>",
"      Feelings of worthlessness or guilt &mdash; The self-perceptions of depressed adolescents usually are marked by feelings of inadequacy, inferiority, failure, and worthlessness. Evaluation of this criterion is challenging because many teens do not directly acknowledge such negative self-perceptions. Guilt about struggling with depression and its associated functional impairment is not considered sufficient to meet this criterion unless it is of delusional proportions. These thoughts may manifest as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reluctance to try to do things (fear of failure)",
"     </li>",
"     <li>",
"      Excessively self-critical assessment of accomplishments",
"     </li>",
"     <li>",
"      Difficulty identifying positive self-attributes",
"     </li>",
"     <li>",
"      Desire to change several aspects of themselves",
"     </li>",
"     <li>",
"      An \"I don't care\" stance to avoid acknowledgment of insecurity",
"     </li>",
"     <li>",
"      Compulsive lying about success or skills to bolster self-esteem",
"     </li>",
"     <li>",
"      Envy or preoccupation with the success of others",
"     </li>",
"     <li>",
"      Marked self reproach or guilt for events that are not their fault",
"     </li>",
"     <li>",
"      Belief that they deserve to be punished for things that are not their fault",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired concentration, indecisiveness &mdash; Depressed adolescents usually have problems with attention and concentration that were not present to the same degree before the episode of depression. Their thinking and processing of information may be slowed. In addition, they are indecisive, which manifests as procrastination, helplessness, or paralysis in taking action. They take longer to complete homework and class work than before the depressive episode; school performance may decline. Information from the school is necessary to evaluate this criterion because school performance typically is affected by the cognitive disturbance.",
"     </li>",
"     <li>",
"      Recurring thoughts of death or suicide &mdash; This criterion is met if the adolescent experiences recurrent thoughts of death (not just fear of death) or suicide, or attempts suicide. Morbid thoughts are common in depressed teens and manifest as: thoughts that life is not worth living, thoughts that others would be better off if the adolescent were dead, or preoccupation with music and literature that has morbid themes.",
"      <br/>",
"      <br/>",
"      In a subset of depressed teens, morbid thoughts devolve to thoughts of suicide, suicide plans, suicide pacts, and suicide attempts. Thoughts that contribute to suicidality include pervasive hopelessness (eg, negative expectations for the future) and a view of suicide as an option to escape emotional pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"       \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"      </a>",
"      .) Adolescents with depression that includes psychotic features sometimes experience command hallucinations telling them to commit suicide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Features",
"    </span>",
"    &nbsp;&mdash;&nbsp;When MDD is identified, the clinician specifies if the disorder has a postpartum onset or seasonal pattern, or if the current episode is marked by psychotic, catatonic, melancholic, or atypical features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postpartum onset is specified when the episode begins within four weeks postpartum.",
"     </li>",
"     <li>",
"      Seasonal pattern is specified when a regular temporal relationship exists between the onset of episodes and a particular time of the year (eg, fall or winter).",
"     </li>",
"     <li>",
"      Psychotic features are specified when delusions or hallucinations are present; the content of the delusions or hallucinations typically is congruent with depressive themes (eg, delusions of guilt or berating auditory hallucinations). Mood-incongruent psychotic features are associated with a poorer prognosis.",
"     </li>",
"     <li>",
"      Catatonia is specified when marked, purposeless psychomotor disturbance such as motoric immobility, waxy flexibility (tendency to maintain posture imposed by another), excessive motor activity, mutism, echolalia, posturing, grimacing, or stupor are present.",
"     </li>",
"     <li>",
"      Melancholic symptoms are specified with loss of pleasure in all or almost all activities or a lack of reactivity in mood. In addition, the quality of depressed mood is different from the feeling experienced after the death or loss of a loved one, and vegetative symptoms (eg, terminal insomnia, psychomotor disturbance, and anorexia or weight loss) typically are present. Melancholic features are more likely to be present in older adults and tend to occur in those suffering from severe depression.",
"     </li>",
"     <li>",
"      Atypical features are specified when mood reactivity, considerable sensitivity to interpersonal rejection, hypersomnia, increased appetite, and the experience of body",
"      <span class=\"nowrap\">",
"       inertia/sensation",
"      </span>",
"      of weighted limbs are present. Adolescents often present with atypical features; adults with atypical features tend to report onset during adolescence, and they frequently have a more chronic, less episodic course, with only partial interepisode recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dysthymic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of DD are less intense but more persistent than those of MDD. DD in adolescents is characterized by chronically depressed or irritable mood for at least one year (in adults, the criterion is two years), plus at least two of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Appetite disturbance",
"     </li>",
"     <li>",
"      Sleep disturbance",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Low self-esteem",
"     </li>",
"     <li>",
"      Poor concentration",
"     </li>",
"     <li>",
"      Difficulty making decisions",
"     </li>",
"     <li>",
"      Feelings of hopelessness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to MDD, DD can present with atypical features. Dysthymic adolescents frequently are disobedient and feel inadequate and irritable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/51\">",
"     51",
"    </a>",
"    ]. DD symptoms often are overlooked because they are not as severe as those of MDD. However, they cause as much, or more, impairment in psychosocial functioning because of their extended course [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Depressive disorder not otherwise specified",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an adolescent presents with clinically significant depressive symptoms but does not meet criteria for any specific mood disorder or adjustment disorder with depressed mood, a diagnosis of depressive disorder not otherwise specified is made. Examples of clinical presentations that qualify as depressive disorder not otherwise specified include a recurrent mild depressive disturbance that does not meet criteria for dysthymia or non-stress-related depressive episodes that do not meet criteria for MDD.",
"   </p>",
"   <p>",
"    Depression, independent of the type, results in problems with daily functioning and development. It is important that it be addressed to prevent a worsening of symptoms and problems in daily life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for depression in adolescents includes mood disorder related to a general medical condition, substance-induced mood disorder, bereavement, adjustment disorder with depressed mood, and bipolar disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mood disorder related to a medical condition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of mood disorder related to a general medical condition is made when an adolescent presents with prominent and persistent disturbance in mood as a physiologic effect of a general medical condition. Considerations to make this diagnosis include presence of a temporal association between the onset, exacerbation, or remission of the general medical condition and the mood disturbance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of features that are not typical of primary mood disorders (eg, absence of family history, or atypical age of onset or clinical course). General medical conditions that might manifest as depression in adolescents include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endocrine &mdash; hypothyroidism, Addison's disease",
"     </li>",
"     <li>",
"      Neurologic &mdash; postconcussive syndrome",
"     </li>",
"     <li>",
"      Metabolic &mdash; vitamin B12 deficiency",
"     </li>",
"     <li>",
"      Autoimmune &mdash; systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Infectious &mdash; mononucleosis, human immunodeficiency virus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Substance-induced mood disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of substance-induced mood disorder is made if the mood disturbance is judged to be a direct consequence of a substance (eg, drug of abuse, medication, toxin). Considerations for this diagnosis include onset, course, and atypical presentations. For drugs of abuse (eg, alcohol, cocaine, opiates, amphetamines), evidence of intoxication or withdrawal must be present. Medications that might be related to depressive symptoms include oral contraceptives, systemic corticosteroids, neuroleptics, stimulants, and anticonvulsants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bereavement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bereavement is a normal reaction to the loss of a loved one. Symptoms characteristic of a depressive episode may be present, but depressive disorder is not typically diagnosed unless the symptoms persist for several months beyond the acute loss and are not characteristic of a \"normal\" grief reaction. Examples of such uncharacteristic grief include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged and marked functional impairment",
"     </li>",
"     <li>",
"      Preoccupation or deep sense of worthlessness",
"     </li>",
"     <li>",
"      Marked psychomotor retardation",
"     </li>",
"     <li>",
"      Suicidal ideation (beyond thoughts of wanting to join the deceased)",
"     </li>",
"     <li>",
"      Psychosis (other than hallucinatory experiences related to seeing or hearing the deceased person)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adjustment disorder with depressed mood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not a depressive disorder, depressed mood is an essential symptom of adjustment disorder with depressed mood (ADDM). An adjustment disorder is a clinically significant emotional or behavioral reaction to an identifiable psychosocial stressor (eg, parental divorce, academic failure, or peer problems). ADDM should be considered if the depressive symptoms are clinically significant, develop within three months of the onset of the stressor(s), and resolve within six months of the termination of the stressor or its consequences. ADDM can persist beyond six months if the stressor is chronic (eg, ongoing parental conflict), and if so, the \"chronic\" specifier should be applied. ADDM should not be diagnosed if the criteria for a depressive disorder are met.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of bipolar disorder is made if the adolescent has had any episode of mania or hypomania in addition to a depressive episode. The risk of bipolar disorder is increased if symptoms such as psychosis, psychomotor retardation, pharmacological induced hypomania, and family history of bipolar disorder are present. Adolescents with bipolar disorder frequently have mixed episodes, with manic and depressive symptoms evident simultaneously, or rapid cycling of manic and depressive symptoms. Mixed episodes and rapid cycling place adolescents at particular risk for suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of depression in adolescents can be difficult because of nonspecific symptoms, comorbidities, and the broad differential diagnosis. Depression in children and adolescents has been misunderstood by youth, parents, and professionals alike. The following closing points provide additional guidelines and issues to consider when evaluating an adolescent for depression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression in adolescents often is undertreated, despite its detrimental effects. An estimated 70 to 80 percent of depressed teenagers do not receive treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/45,59\">",
"       45,59",
"      </a>",
"      ]. Treatment utilization is more common when adolescents present with comorbid disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diagnosis should be based upon a formal clinical interview with the adolescent that is supplemented by information from parents and teachers [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/28,60,61\">",
"       28,60,61",
"      </a>",
"      ]. Standardized instruments such as the Beck Depression Inventory (BDI) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/62\">",
"       62",
"      </a>",
"      ], the Child Depression Inventory (CDI) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/63\">",
"       63",
"      </a>",
"      ], or the Reynolds Adolescent Depression Scale (RADS) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/64\">",
"       64",
"      </a>",
"      ] are useful as screening tools and to monitor functioning, but they should not be used as the basis for diagnosis. The CDI is designed for children 7 to 17 years of age and is available for purchase through Multi-Health Systems, Inc. (",
"      <a class=\"external\" href=\"file://www.mhs.com/\">",
"       www.mhs.com",
"      </a>",
"      ). The RADS is designed for teens in grades 7 through 12 and is published by Psychological Assessment Resources, Inc. (",
"      <a class=\"external\" href=\"file://www.parinc.com/\">",
"       www.parinc.com",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Questions should be phrased in a nonstigmatizing and even somewhat normalizing way, at least at first (eg, \"Everyone I know gets sad sometimes &mdash; what kinds of things usually make you sad? Would you say you're usually happy, sad, or in-between?\"). Particularly for guarded adolescents, more direct questions with empathetic response for their unique experience usually are best tolerated once the adolescent trusts that it is okay to discuss such topics. Scaling questions are helpful for adolescents who have trouble describing their experiences (eg, \"On a scale of 1 to 10, how annoyed have you been lately?\").",
"     </li>",
"     <li>",
"      The evaluation must include assessment for suicidal and homicidal ideation, as well as risk and protective factors that may influence suicide risk [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A comprehensive initial assessment must be done to look for comorbid conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, a thorough investigation must be done to evaluate diagnoses other than depressive disorders (eg, hypothyroidism, substance use or exposure, and other psychiatric disorders).",
"     </li>",
"     <li>",
"      Adolescent depression must be evaluated in the context of precipitants, stressors, and academic, social, and family functioning [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/61\">",
"       61",
"      </a>",
"      ]. These factors will guide appropriate intervention, including a treatment plan that targets symptoms, as well as circumstances that maintain depression and put the adolescent at risk for future episodes.",
"     </li>",
"     <li>",
"      Depression in adolescents is common and often identified in the primary care setting. In some circumstances, the primary care provider successfully manages the intervention, including education of the adolescent and his or her family, recommendations for effective coping, and possibly medication. More often, the primary care providers refer depressed adolescents for additional intervention.",
"     </li>",
"     <li>",
"      Referral to psychiatry, psychology, or another mental health provider (eg, clinical social worker) must be considered when depression is recurrent or chronic; complicated by comorbid conditions, marked functional impairment, or psychosocial factors likely to maintain the depression (eg, a high level of family discord); and especially if the adolescent's presentation is unclear or guarded. Psychotherapy can provide depressed adolescents with a means to better understand and manage their moods, as well as identify and manage psychosocial factors that contribute to the depression, and a place where they can restore a healthy sense of self and relationships.",
"     </li>",
"     <li>",
"      Specialty care is urgently indicated in adolescents with coexisting substance abuse, lack of response to the initial course of treatment, a history of suicide attempt or current suicidal ideation, psychosis, bipolar disorder, or if the family is unable to monitor the adolescent's safety [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5289/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"       \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adolescents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parents may resist the diagnosis of depression and continue to seek a \"medical\" explanation for presenting concerns. In these cases, it often is beneficial to join the adolescent or family members in their understanding of the presenting concern and extend their view with psychoeducation (eg, \"You've been experiencing considerable fatigue that has been immobilizing; it is very common to feel discouraged, annoyed, or even depressed when faced with this kind of stress day in and day out.\")",
"     </li>",
"     <li>",
"      Depression is a disabling and overwhelming illness. Even if they are initially resistant, adolescents and their families often will view the diagnosis of depression as reassuring. The explanation for the symptoms can provide a sense of control and is a significant step toward symptom relief.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"       \"Patient information: Depression treatment options for adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rochlin, G. Griefs and Discontents, Little, Brown, Boston 1965.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/2\">",
"      Rie HE. Depression in childhood. A survey of some pertinent contributions. J Am Acad Child Psychiatry 1966; 5:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/3\">",
"      Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/4\">",
"      Saluja G, Iachan R, Scheidt PC, et al. Prevalence of and risk factors for depressive symptoms among young adolescents. Arch Pediatr Adolesc Med 2004; 158:760.",
"     </a>",
"    </li>",
"    <li>",
"     Kovacs, M, Beck, AT. An empirical clinical approach towards a definition of childhood depression. In: Depression in children: Diagnosis, treatment and conceptual models, Schulterbrant, JG, Raskin, A (Eds), Raven Press, New York 1977. p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/6\">",
"      Carlson GA, Cantwell DP. Unmasking masked depression in children and adolescents. Am J Psychiatry 1980; 137:445.",
"     </a>",
"    </li>",
"    <li>",
"     Hall, GS. Adolescence: Its psychology and its relations to physiology, anthropology, sociology, sex, crime, religion and education, Appleton, New York 1904.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/8\">",
"      Petersen AC. Adolescent development. Annu Rev Psychol 1988; 39:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/9\">",
"      Powers SI, Hauser ST, Kilner LA. Adolescent mental health. Am Psychol 1989; 44:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/10\">",
"      Fleming JE, Offord DR. Epidemiology of childhood depressive disorders: a critical review. J Am Acad Child Adolesc Psychiatry 1990; 29:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/11\">",
"      Lewinsohn PM, Clarke GN, Seeley JR, Rohde P. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 1994; 33:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/12\">",
"      Lewinsohn PM, Hops H, Roberts RE, et al. Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 1993; 102:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/13\">",
"      Lewinsohn PM, Rohde P, Klein DN, Seeley JR. Natural course of adolescent major depressive disorder: I. Continuity into young adulthood. J Am Acad Child Adolesc Psychiatry 1999; 38:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/14\">",
"      Rao U, Hammen C, Daley SE. Continuity of depression during the transition to adulthood: a 5-year longitudinal study of young women. J Am Acad Child Adolesc Psychiatry 1999; 38:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/15\">",
"      Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993; 29:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/16\">",
"      Kessler RC, McGonagle KA, Nelson CB, et al. Sex and depression in the National Comorbidity Survey. II: Cohort effects. J Affect Disord 1994; 30:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/17\">",
"      Nolen-Hoeksema S, Girgus JS. The emergence of gender differences in depression during adolescence. Psychol Bull 1994; 115:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/18\">",
"      Hankin BL, Abramson LY, Moffitt TE, et al. Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol 1998; 107:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/19\">",
"      Kutcher S, Marton P. Affective disorders in first-degree relatives of adolescent onset bipolars, unipolars, and normal controls. J Am Acad Child Adolesc Psychiatry 1991; 30:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/20\">",
"      Warner V, Weissman MM, Mufson L, Wickramaratne PJ. Grandparents, parents, and grandchildren at high risk for depression: a three-generation study. J Am Acad Child Adolesc Psychiatry 1999; 38:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/21\">",
"      Lewinsohn PM, Roberts RE, Seeley JR, et al. Adolescent psychopathology: II. Psychosocial risk factors for depression. J Abnorm Psychol 1994; 103:302.",
"     </a>",
"    </li>",
"    <li>",
"     Rutter, M. Children of sick parents: An environment and psychiatric study, Oxford University Press, London 1966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/23\">",
"      Reinherz HZ, Giaconia RM, Pakiz B, et al. Psychosocial risks for major depression in late adolescence: a longitudinal community study. J Am Acad Child Adolesc Psychiatry 1993; 32:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/24\">",
"      Adrian C, Hammen C. Stress exposure and stress generation in children of depressed mothers. J Consult Clin Psychol 1993; 61:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/25\">",
"      Garber, J, Hilsman, R. Cognition, stress and depression in children and adolescents. Child Adolesc Psychiatr Clin N Am 1992; 1:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/26\">",
"      Hilsman R, Garber J. A test of the cognitive diathesis-stress model of depression in children: academic stressors, attributional style, perceived competence, and control. J Pers Soc Psychol 1995; 69:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/27\">",
"      Burke P, Elliott M. Depression in pediatric chronic illness. A diathesis-stress model. Psychosomatics 1999; 40:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/28\">",
"      Zuckerbrot RA, Cheung AH, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial management. Pediatrics 2007; 120:e1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/29\">",
"      Kendler KS. Genetic epidemiology in psychiatry. Taking both genes and environment seriously. Arch Gen Psychiatry 1995; 52:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/30\">",
"      Williamson DE, Birmaher B, Frank E, et al. Nature of life events and difficulties in depressed adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/31\">",
"      Gershon ES, Hamovit JH, Guroff JJ, Nurnberger JI. Birth-cohort changes in manic and depressive disorders in relatives of bipolar and schizoaffective patients. Arch Gen Psychiatry 1987; 44:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/32\">",
"      Klein DN, Riso LP, Donaldson SK, et al. Family study of early-onset dysthymia. Mood and personality disorders in relatives of outpatients with dysthymia and episodic major depression and normal controls. Arch Gen Psychiatry 1995; 52:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/33\">",
"      Ryan ND, Williamson DE, Iyengar S, et al. A secular increase in child and adolescent onset affective disorder. J Am Acad Child Adolesc Psychiatry 1992; 31:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/34\">",
"      Asarnow JR, Jaycox LH, Duan N, et al. Depression and role impairment among adolescents in primary care clinics. J Adolesc Health 2005; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/35\">",
"      Egger HL, Costello EJ, Erkanli A, Angold A. Somatic complaints and psychopathology in children and adolescents: stomach aches, musculoskeletal pains, and headaches. J Am Acad Child Adolesc Psychiatry 1999; 38:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/36\">",
"      Bernstein GA, Massie ED, Thuras PD, et al. Somatic symptoms in anxious-depressed school refusers. J Am Acad Child Adolesc Psychiatry 1997; 36:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/37\">",
"      Deykin EY, Buka SL, Zeena TH. Depressive illness among chemically dependent adolescents. Am J Psychiatry 1992; 149:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/38\">",
"      Brown RA, Lewinsohn PM, Seeley JR, Wagner EF. Cigarette smoking, major depression, and other psychiatric disorders among adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/39\">",
"      Cicchetti D, Toth SL. The development of depression in children and adolescents. Am Psychol 1998; 53:221.",
"     </a>",
"    </li>",
"    <li>",
"     Joiner, T, Coyne, JC. The Interactional Nature of Depression, American Psychological Association, Washington DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/41\">",
"      Beasley PJ, Beardslee WR. Depression in the adolescent patient. Adolesc Med 1998; 9:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/42\">",
"      Bernstein GA. Comorbidity and severity of anxiety and depressive disorders in a clinic sample. J Am Acad Child Adolesc Psychiatry 1991; 30:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/43\">",
"      Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry 1993; 32:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/44\">",
"      Garland EJ. Adolescent depression. Part 1. Diagnosis. Can Fam Physician 1994; 40:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/45\">",
"      Rohde P, Lewinsohn PM, Seeley JR. Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults. J Abnorm Psychol 1991; 100:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/46\">",
"      Kovacs M, Paulauskas S, Gatsonis C, Richards C. Depressive disorders in childhood. III. A longitudinal study of comorbidity with and risk for conduct disorders. J Affect Disord 1988; 15:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/47\">",
"      Lewinsohn PM, Rohde P, Seeley JR. Adolescent psychopathology: III. The clinical consequences of comorbidity. J Am Acad Child Adolesc Psychiatry 1995; 34:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/48\">",
"      Fombonne E, Wostear G, Cooper V, et al. The Maudsley long-term follow-up of child and adolescent depression. 1. Psychiatric outcomes in adulthood. Br J Psychiatry 2001; 179:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/49\">",
"      Fombonne E, Wostear G, Cooper V, et al. The Maudsley long-term follow-up of child and adolescent depression. 2. Suicidality, criminality and social dysfunction in adulthood. Br J Psychiatry 2001; 179:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/50\">",
"      Goodyer IM, Herbert J, Secher SM, Pearson J. Short-term outcome of major depression: I. Comorbidity and severity at presentation as predictors of persistent disorder. J Am Acad Child Adolesc Psychiatry 1997; 36:179.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/52\">",
"      Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996; 35:705.",
"     </a>",
"    </li>",
"    <li>",
"     Beck, AT. Depression: Clinical, experimental, and theoretical aspects, Hoeber, New York 1967. (Republished as Depression: Causes and treatment, University of Pennsylvania Press, Philadelphia 1972.).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/54\">",
"      Lehrer JA, Shrier LA, Gortmaker S, Buka S. Depressive symptoms as a longitudinal predictor of sexual risk behaviors among US middle and high school students. Pediatrics 2006; 118:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/55\">",
"      Mitchell J, McCauley E, Burke PM, Moss SJ. Phenomenology of depression in children and adolescents. J Am Acad Child Adolesc Psychiatry 1988; 27:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/56\">",
"      Allgood-Merten B, Lewinsohn PM, Hops H. Sex differences and adolescent depression. J Abnorm Psychol 1990; 99:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/57\">",
"      Kovacs M, Akiskal HS, Gatsonis C, Parrone PL. Childhood-onset dysthymic disorder. Clinical features and prospective naturalistic outcome. Arch Gen Psychiatry 1994; 51:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/58\">",
"      Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1997; 36:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/59\">",
"      Keller MB, Lavori PW, Beardslee WR, et al. Depression in children and adolescents: new data on 'undertreatment' and a literature review on the efficacy of available treatments. J Affect Disord 1991; 21:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/60\">",
"      Brent DA, Birmaher B. Clinical practice. Adolescent depression. N Engl J Med 2002; 347:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/61\">",
"      Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/62\">",
"      BECK AT, WARD CH, MENDELSON M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5289/abstract/63\">",
"      Kovacs M. Rating scales to assess depression in school-aged children. Acta Paedopsychiatr 1981; 46:305.",
"     </a>",
"    </li>",
"    <li>",
"     Reynolds, WM. Adolescent Depression Scale, Psychological Assessment Resources, Inc, Odessa, FL 1987.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1224 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5A1610FE52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5289=[""].join("\n");
var outline_f5_10_5289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMPACT OF DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Major depressive disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Phenomenology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dysthymic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Depressive disorder not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mood disorder related to a medical condition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Substance-induced mood disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bereavement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adjustment disorder with depressed mood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=related_link\">",
"      Overview of treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4328?source=related_link\">",
"      Psychosocial treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_10_5290="Choosing the route of delivery after cesarean birth";
var content_f5_10_5290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Choosing the route of delivery after cesarean birth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5290/contributors\">",
"     C Edward Wells, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5290/contributors\">",
"     F Gary Cunningham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5290/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5290/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5290/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/10/5290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/10/5290/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/10/5290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15065246\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimum management of the woman who has undergone a previous cesarean delivery has been debated for over 100 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The increasing primary cesarean delivery rate in recent decades has led to large numbers of women undergoing repeat cesarean deliveries and multiple cesarean deliveries. In 1980, a National Institutes of Health (NIH) Consensus Development Conference report questioned the necessity of routine repeat cesarean delivery and, with endorsement from the American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], encouraged attempts to increase the rate of trial of labor after cesarean delivery (TOLAC). These attempts were highly successful; rates of vaginal birth after previous cesarean (VBAC) increased from 3.4 percent in 1980 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/10\">",
"     10",
"    </a>",
"    ] to a peak of 28.3 percent in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/11\">",
"     11",
"    </a>",
"    ], along with a concomitant decline in total cesarean delivery rates for the United States (",
"    <a class=\"graphic graphic_figure graphicRef74373 \" href=\"UTD.htm?29/59/30654\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the VBAC rate increased, however, so did reports of uterine rupture-related maternal and perinatal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. These adverse outcomes dampened enthusiasm for TOLAC. They also prompted ACOG to issue a practice bulletin in 1998 that cautioned TOLAC should only be attempted in appropriately equipped institutions with physicians &lsquo;readily&rsquo; available to provide emergency care [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/18\">",
"     18",
"    </a>",
"    ]. Within nine months, ACOG revised the practice bulletin to say that physicians should be &lsquo;immediately&rsquo; available [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/19\">",
"     19",
"    </a>",
"    ], a position endorsed by the American Society of Anesthesiologists (ASA) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This one-word change, from &lsquo;readily&rsquo; to &lsquo;immediately&rsquo; available, may have been the most important factor responsible for the decade-long decline in national VBAC rates, reaching a low of 8 percent in 2007 (",
"    <a class=\"graphic graphic_figure graphicRef74373 \" href=\"UTD.htm?29/59/30654\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Two surveys of hospital administrators found that 30 percent of hospitals discontinued allowing TOLAC because they were unable to comply with the immediately available requirement for surgical and anesthesia services and, of the hospitals who continued to offer TOLAC, over half made changes in their policies to accommodate ACOG recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Ironically, during this same decade, there were continuing reports describing the success and safety of TOLAC in selected clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of interrelated factors, both medical and nonmedical, have contributed to declining TOLAC rates. Concerns about medical liability claims have contributed to reduced access to TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. A 2009 Survey of Professional Liability by ACOG found that 91 percent of members who responded reported at least one liability claim against them in their career; 62 percent of claims within the survey period were related to obstetric care [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/30\">",
"     30",
"    </a>",
"    ]. Of those who made changes in their obstetric practice as a result of risk or fear of liability, 25 percent stopped offering TOLAC. Another survey of private practice obstetricians also reported that the risk of liability was an important reason cited for no longer offering TOLAC to their patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/32\">",
"     32",
"    </a>",
"    ]. Efforts at medical malpractice tort reform may prompt a change in this trend [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little information on provider views or preferences regarding the practices and policies of TOLAC. In addition to",
"    <span class=\"nowrap\">",
"     medicolegal/liability",
"    </span>",
"    concerns and",
"    <span class=\"nowrap\">",
"     ACOG/ASA",
"    </span>",
"    requirements for providers and institutions offering TOLAC, fear of catastrophic complications associated with TOLAC may be another reason providers avoid encouraging it for their patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,34\">",
"     25,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2010, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Office of Medical Applications of Research (OMAR) of the NIH convened a Consensus Development Conference to study these issues [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25\">",
"     25",
"    </a>",
"    ]. Their final report summarized the state-of-knowledge concerning the risks and benefits of elective repeat cesarean delivery (ERCD) versus TOLAC in women who have undergone one or more prior cesarean deliveries. These findings are described throughout this topic review, along with summaries of recommendations of various professional organizations regarding the approach to management of a woman with a prior cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065253\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planning the route of delivery for the woman who has had a previous cesarean delivery should be addressed early in her prenatal care, and can even begin preconceptionally. There are two choices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TOLAC with the goal of achieving VBAC. If cesarean delivery becomes necessary, then it is termed a &ldquo;failed TOLAC.&rdquo; Overall, the success rate for women who attempt TOLAC is approximately 75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34\">",
"       34",
"      </a>",
"      ]. This rate varies among institutions and providers, and is affected by various antepartum, intrapartum, and nonmedical factors (discussed below).",
"     </li>",
"     <li>",
"      ERCD, which includes scheduled cesarean delivery, as well as planned but unscheduled cesareans performed because spontaneous labor or another indication resulted in the need for delivery before the scheduled date.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision for TOLAC or ERCD should be made by the woman in consultation with her provider. No high-quality trials have been performed comparing the risks and benefits of TOLAC versus ERCD. &nbsp;",
"   </p>",
"   <p>",
"    With either approach, women who have undergone a prior cesarean delivery are at risk for serious maternal and perinatal complications and should be counseled about the risk and significance of these complications. Importantly, individual patient factors that affect the risks and benefits for each delivery route should be discussed. This is especially important for women who are potentially at higher risk of uterine rupture and its attendant sequelae (see",
"    <a class=\"local\" href=\"#H15065566\">",
"     'Possibly appropriate candidates'",
"    </a>",
"    below). The decision should also be based on consideration of factors known to affect TOLAC success rates. Ongoing discussion at intervals throughout pregnancy is important, as conditions may arise that alter the risks versus benefits of the planned route of delivery (",
"    <a class=\"graphic graphic_table graphicRef63673 \" href=\"UTD.htm?10/36/10828\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15065260\">",
"     'Factors affecting success rate of TOLAC'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15065383\">",
"     'Risks and benefits of TOLAC and ERCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A woman&rsquo;s decision regarding route of delivery is influenced by a variety of factors, in addition to",
"    <span class=\"nowrap\">",
"     obstetrical/perinatal",
"    </span>",
"    risks, success rate, and availability. Women report that their health care providers&rsquo; recommendations and preferences exert a strong influence on their decision whether or not to pursue TOLAC. Other factors underlying women&rsquo;s preference for TOLAC include prior successful vaginal delivery, future pregnancy plans, family obligations making a speedy return to normal activities postpartum desirable, and desire for their partners&rsquo; involvement in labor and birth. Factors identified as advantages of scheduled ERCD include scheduling convenience, ease of sterilization at the time of delivery, and fear of failed trial of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,34\">",
"     25,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065260\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING SUCCESS RATE OF TOLAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, overall, women who attempt TOLAC have an approximate 75 percent success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34\">",
"     34",
"    </a>",
"    ]. The rate varies among institutions and providers, and is affected by various antepartum, intrapartum, and nonmedical factors (discussed below) (",
"    <a class=\"graphic graphic_table graphicRef53341 \" href=\"UTD.htm?4/0/4108\">",
"     table 2",
"    </a>",
"    ). The highest success rates (over 80 percent) are found among women who have had a successful vaginal delivery before or after their cesarean, who present in active labor, and in whom the indication for the prior cesarean delivery was fetal malpresentation. Conversely, women who have never had a vaginal delivery, need labor induction (especially with an unfavorable cervix), had a previous cesarean for failure to progress or nonreassuring tracing, have a macrosomic infant, or are postterm have a reduced likelihood of a successful TOLAC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065269\">",
"    <span class=\"h2\">",
"     Antepartum factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9335477\">",
"    <span class=\"h3\">",
"     Indication for prior cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of successful TOLAC by indication for prior cesarean delivery is 75 percent for fetal malpresentation, 60 percent for nonreassuring fetal heart rate pattern, and 54 percent for failure to progress or cephalopelvic disproportion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9335484\">",
"    <span class=\"h3\">",
"     History of prior vaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have had a vaginal delivery before or after their previous cesarean delivery are significantly more likely to have a successful TOLAC than those who have never delivered vaginally (OR for successful TOLAC with prior vaginal delivery 3.90, 95% CI 3.60-4.30; with prior VBAC 4.76, 95% CU 4.35-5.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/35-41\">",
"     35-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065277\">",
"    <span class=\"h3\">",
"     Demographic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hispanic, African American, and Asian women are more likely to pursue a TOLAC, but are less likely to have a successful VBAC when compared with non-Hispanic and white women (OR for successful TOLAC for Caucasians, African Americans, and Hispanics: 1, 0.69, 0.65 respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34,35,42-45\">",
"     34,35,42-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing maternal age, single marital status, and less than 12 years of education are also associated with a reduced likelihood of successful TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34,35,43,46\">",
"     34,35,43,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women over age 35 are less likely to pursue a TOLAC; those who attempt TOLAC are less likely to have a successful VBAC and more likely to experience TOLAC-associated complications than younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of successful TOLAC increases with increasing maternal height (for each 5 cm maternal height increase the OR for successful TOLAC is 1.33, 95% CI 1.28-1.37) and is lower in obese women (for BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    the OR for successful TOLAC is 0.55, 95% CI 0.51-0.60) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/35,42,48\">",
"     35,42,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interpregnancy interval of less than six months is an independent risk factor for both uterine rupture and maternal morbidity during TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065298\">",
"    <span class=\"h3\">",
"     Maternal medical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the effect of preexisting maternal medical disease on the outcome of a TOLAC are inconclusive. Several cohort studies of women with preexisting maternal disease, such as hypertension, diabetes, asthma, renal disease, and heart disease, reported a reduced likelihood of successful TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/35,36,44\">",
"     35,36,44",
"    </a>",
"    ]. In one prospective study, however, there were no significant differences in the rates of successful TOLAC in women with these medical disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065305\">",
"    <span class=\"h2\">",
"     Intrapartum factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065313\">",
"    <span class=\"h3\">",
"     Admission labor status",
"    </span>",
"    &nbsp;&mdash;&nbsp;When admitted to the labor unit, women in spontaneous labor or with a high bishop score are more likely to have successful TOLAC than women who are being induced or who have low Bishop scores (ORs for successful TOLAC with spontaneous labor, induction, augmentation 1.0, 0.50, 0.68, respectively; for admission cervical examination &gt;4cm 2.56, 95% CI 2.38-2.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065320\">",
"    <span class=\"h3\">",
"     Fetal macrosomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fetus weighing more than 4000 g reduces the likelihood of successful TOLAC (OR for successful TOLAC for birth weight &gt;4000 g 0.55, 95% CI 0.49-0.61) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34,35,50,51\">",
"     34,35,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065327\">",
"    <span class=\"h3\">",
"     Type of hospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;University hospitals or those affiliated with an obstetrics and gynecology residency program have higher rates of TOLAC and successful VBAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/46,51,52\">",
"     46,51,52",
"    </a>",
"    ]. Women who deliver at a private or rural hospital have a decreased likelihood that TOLAC will be attempted, and if attempted, a decreased rate of successful VBAC when compared to a tertiary care or perinatal center [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34\">",
"     34",
"    </a>",
"    ]. As an example, a study that compared VBAC rates across hospital settings in California reported rates of VBAC (adjusted for baseline and medical characteristics of mother and fetus) were 14 percent in private nonteaching hospitals, 57 percent in public hospitals, 60 percent in private teaching hospitals, and 41 percent in health maintenance organizations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065383\">",
"    <span class=\"h1\">",
"     RISKS AND BENEFITS OF TOLAC AND ERCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three possible outcomes for the woman who has had a prior cesarean delivery: a successful trial of labor culminating in vaginal birth (successful VBAC), an unsuccessful TOLAC resulting in a repeat cesarean delivery, or an ERCD. The benefits of TOLAC are closely related to having a successful vaginal birth, which is associated with the lowest morbidity of the three possibilities. The highest risks for maternal and neonatal morbidity are associated with unsuccessful TOLAC that culminates in a repeat cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When counseling women concerning the risks and benefits of TOLAC versus ERCD, it is important to recognize that many studies that compared these two routes of delivery reported maternal and neonatal outcomes based on the",
"    <strong>",
"     actual",
"    </strong>",
"    route of delivery rather than the",
"    <strong>",
"     intended",
"    </strong>",
"    route. If this type of analysis is performed, the outcomes of women who undergo cesarean delivery after an unsuccessful TOLAC are grouped along with the outcomes of women undergoing ERCD. In addition, the outcomes of women who planned ERCD, but spontaneously labored and were delivered vaginally, are grouped along with the outcomes of women who had a successful VBAC. This method of analysis leads to misleading conclusions about the actual risk of adverse events or outcomes associated with the decision to attempt TOLAC or ERCD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,34,54\">",
"     25,34,54",
"    </a>",
"    ]. Analysis of available data is also complicated by imprecise definitions and outcome measurements, as well as difficulties encountered when trying to characterize events and outcomes attributable to route of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18437956\">",
"    <span class=\"h2\">",
"     Overall estimated risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NICHD consensus conference panel determined the following risk estimates based on data obtained by systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34,54\">",
"     34,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a hypothetical group of 100,000 women of",
"      <strong>",
"       any",
"      </strong>",
"      gestational age who undergo TOLAC, there will be 4 maternal deaths, 468 cases of uterine rupture, and 133 perinatal deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a hypothetical group of 100,000 women of",
"      <strong>",
"       any",
"      </strong>",
"      gestational age who undergo ERCD, there will be 13 maternal deaths, 26 uterine ruptures, and 50 perinatal deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In terms of absolute risk for the woman undergoing TOLAC, 1 in 1000 trials of labor will result in neonatal death or significant neurological injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/55\">",
"     55",
"    </a>",
"    ]. Specifically, 1 in 100 trials will result in uterine rupture, and 1 in 10 uterine ruptures will result in neonatal death or neurological injury. The absolute risk of uterine rupture with ERCD is 0.026 percent (95% CI 0.009-0.082%) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34\">",
"     34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065390\">",
"    <span class=\"h2\">",
"     Maternal risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following table summarizes available evidence on maternal risks of TOLAC and ERCD (",
"    <a class=\"graphic graphic_table graphicRef65114 \" href=\"UTD.htm?25/62/26604\">",
"     table 3",
"    </a>",
"    ). These data were derived from a systematic review of 41 studies on the maternal outcomes for trial of labor versus ERCD that reported on the actual route of delivery rather than the intended route.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Uterine rupture",
"      </strong>",
"      - Uterine rupture is a life-threatening pregnancy complication; it is rare (in resource-rich countries), but when it occurs, it is most often associated with TOLAC. The term refers to complete disruption of all uterine layers, including the serosa. It often leads to maternal hemorrhage and adverse fetal outcomes. By comparison, uterine dehiscence generally refers to an incomplete, and frequently clinically occult, uterine scar separation where the serosa remains intact, and is not usually associated with hemorrhage or adverse outcomes. (See",
"      <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=see_link\">",
"       \"Uterine rupture after previous cesarean delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Infection",
"      </strong>",
"      - There is no significant difference between TOLAC and ERCD in maternal infection rate (",
"      <a class=\"graphic graphic_table graphicRef65114 \" href=\"UTD.htm?25/62/26604\">",
"       table 3",
"      </a>",
"      ). While intrapartum chorioamnionitis is more common with TOLAC, the incidence of postpartum pelvic infection is lower after a successful TOLAC than after either ERCD or cesarean delivery following an unsuccessful TOLAC [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Peripartum hysterectomy",
"      </strong>",
"      - The risk of peripartum hysterectomy in women with a prior cesarean delivery is about 0.3 percent, with no significant differences based on planned or actual route of delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/28,34\">",
"       28,34",
"      </a>",
"      ]. Although some of these procedures are performed because of uterine rupture, many are due to placenta accreta, which becomes more prevalent with an increasing number of cesarean deliveries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link&amp;anchor=H3937600#H3937600\">",
"       \"Clinical features and diagnosis of placenta accreta, increta, and percreta\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hemorrhage and transfusion",
"      </strong>",
"      - Data comparing the risk of hemorrhage or blood transfusion for TOLAC versus ERCD are sparse, but do not indicate a significant difference (",
"      <a class=\"graphic graphic_table graphicRef65114 \" href=\"UTD.htm?25/62/26604\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Pelvic floor injury",
"      </strong>",
"      - There are few data about long-term effects on the pelvic floor after TOLAC versus ERCD [",
"      <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25\">",
"       25",
"      </a>",
"      ]. ERCD avoids the risk of perineal trauma during labor and vaginal birth, and any attendant sequelae. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"       \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065481\">",
"    <span class=\"h2\">",
"     Maternal benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of successful TOLAC derive from avoidance of risks associated with repeat cesarean delivery. Immediate benefits of TOLAC include shorter hospital stay, fewer postpartum complications, quicker return to normal activities, and lower maternal morbidity and mortality. Long-term, the potential complications that accrue with multiple cesarean deliveries can be avoided.",
"   </p>",
"   <p>",
"    The benefits of ERCD are scheduling convenience, ease of sterilization at the time of delivery, and avoidance of the risks associated with failed TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=see_link&amp;anchor=H3#H3\">",
"     \"Cesarean delivery: Postoperative issues\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=see_link&amp;anchor=H6#H6\">",
"     \"Repeat cesarean delivery\", section on 'Is there an unsafe number of repeat cesarean deliveries?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065488\">",
"    <span class=\"h2\">",
"     Perinatal risks and benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little or no evidence on short- and long-term neonatal outcomes after TOLAC versus ERCD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25\">",
"     25",
"    </a>",
"    ]. As discussed above, most of the available evidence documents differences comparing",
"    <strong>",
"     actual",
"    </strong>",
"    rather than",
"    <strong>",
"     intended",
"    </strong>",
"    mode of delivery, and is of low quality due to inconsistent and imprecise outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065495\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;TOLAC is associated with significantly higher perinatal mortality and neonatal mortality rates compared with ERCD (perinatal mortality rate: 0.13 versus 0.05 percent; neonatal mortality rate: 0.11 versus 0.06) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,34\">",
"     25,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065502\">",
"    <span class=\"h3\">",
"     Hypoxic ischemic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;TOLAC appears to be associated with a higher risk of hypoxic ischemic encephalopathy than ERCD. The Maternal Fetal Medicine Networks Unit study of over 33,000 women with a prior cesarean delivery reported the incidence of hypoxic ischemic encephalopathy at term was 46 per 100,000 TOLACS compared with zero cases in women undergoing ERCD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065509\">",
"    <span class=\"h3\">",
"     Respiratory problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of pooled data suggests that the absolute risk of transient tachypnea of the newborn is slightly higher with ERCD compared with TOLAC (4.2 versus 3.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/54\">",
"     54",
"    </a>",
"    ]. However, neonatal bag and mask ventilation was used more often in infants delivered following TOLAC than in those delivered by ERCD (5.4 versus 2.5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065516\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no significant differences in five-minute Apgar scores or neonatal intensive care unit admissions when infants delivered by TOLAC are compared with those delivered by ERCD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Birth trauma from lacerations is more commonly seen in infants born by ERCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18438373\">",
"    <span class=\"h1\">",
"     OPTIMUM CANDIDATES FOR TOLAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paucity of definitive data that are predictive of maternal and fetal outcome (successful or unsuccessful) from TOLAC makes determining the ideal candidates for a trial of labor a challenge. A number of predictive models, screening tools, and nomograms have been developed for this purpose, but none have been proven to be clinically useful [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,34,42\">",
"     25,34,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18438126\">",
"    <span class=\"h2\">",
"     Screening tools and decision aids for choosing the route of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening tools and decision aids have been developed to help predict the likelihood of successful TOLAC and to help patients understand the risks and benefits of TOLAC versus ERCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18438133\">",
"    <span class=\"h3\">",
"     Provider screening tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, a reliable screening tool can help identify women with a prior cesarean delivery who have a high or low likelihood of successful TOLAC. Current screening tools use a combination of obstetric factors, such as maternal demographics (age, race, ethnicity, BMI); the indication(s) for the prior cesarean delivery; the type and number of prior hysterotomy incisions; previous vaginal deliveries, either before or after the cesarean delivery; cervical favorability (eg, Bishop score at the time of admission for spontaneous or planned induction of labor); and intrapartum interventions (eg, labor induction or augmentation) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25\">",
"     25",
"    </a>",
"    ]. One review concluded that currently used scored screening tool models incorporating various combinations of the above predictive factors reasonably predicted successful TOLAC, but were unable to consistently identify women at risk for failed TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18438140\">",
"    <span class=\"h3\">",
"     Patient decision aids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of patient-oriented information and decision aids are available to help patients make an informed decision about TOLAC versus ERCD. Patient information is available from ACOG at",
"    <a class=\"external\" href=\"file://www.acog.org/publications/patient\">",
"     www.acog.org/publications/patient",
"    </a>",
"    <span class=\"nowrap\">",
"     education/bp006.cfm",
"    </span>",
"    and from the National Library of Medicine at",
"    <span class=\"nowrap\">",
"     www.nlm.nih.gov/medlineplus/ency/article/002911.htm.",
"    </span>",
"   </p>",
"   <p>",
"    Additionally, there are online tools or decision aides that can be used as an adjunct to provider consultation. They are designed to communicate evidence-based information to help patients better understand childbirth choices, establish their personal priorities, and ultimately decide whether or not to pursue a TOLAC. One example is from the Mayo Clinic: Vaginal Birth After C-section and is available at",
"    <span class=\"nowrap\">",
"     file://www.mayoclinic.com/health/vbac/MY01143.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065552\">",
"    <span class=\"h2\">",
"     Recommendations by national organizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following guidelines were developed by a panel of the NICHD consensus conference on delivery after prior cesarean and by ACOG (",
"    <a class=\"graphic graphic_table graphicRef51829 \" href=\"UTD.htm?42/22/43372\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,34,57\">",
"     25,34,57",
"    </a>",
"    ]. The NICHD concluded: &ldquo;Given the available evidence, trial of labor is a reasonable option for many pregnant women with one prior low transverse uterine incision. The data reviewed in this report show that both trial of labor and elective repeat cesarean delivery for a pregnant woman with one prior transverse uterine incision have important risks and benefits and that these risks and benefits differ for the woman and her fetus. When trial of labor and elective repeat cesarean delivery are medically equivalent options, a shared decision-making process should be adopted and, whenever possible, the woman&rsquo;s preference should be honored&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,34\">",
"     25,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations from other professional societies are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef74165 \" href=\"UTD.htm?27/41/28316\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18441899\">",
"    <span class=\"h3\">",
"     Appropriate candidates",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065559\">",
"    <span class=\"h4\">",
"     One prior low transverse uterine incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good and consistent evidence that a woman who has undergone only one previous cesarean delivery performed using a transverse lower segment hysterotomy incision has a very low risk of uterine scar separation during a subsequent trial of labor; thus, TOLAC is a reasonable option for delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,34\">",
"     25,34",
"    </a>",
"    ]. For these women, the bulk of evidence supports a success rate of TOLAC approaching 60 to 70 percent, with a predicted uterine rupture rate of about 0.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/34\">",
"     34",
"    </a>",
"    ]. Success rates are higher in patients with additional characteristics, such as a prior vaginal delivery. (See",
"    <a class=\"local\" href=\"#H15065260\">",
"     'Factors affecting success rate of TOLAC'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065566\">",
"    <span class=\"h3\">",
"     Possibly appropriate candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding risk of uterine rupture in the following situations are more limited and based on sparse or inconsistent scientific evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"     57",
"    </a>",
"    ]. ACOG recommends that after individualized risk assessment and counseling, patients in the following situations be considered candidates for TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065573\">",
"    <span class=\"h4\">",
"     Prior low vertical uterine incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from reports beginning in the 1980s are limited and inconclusive regarding TOLAC outcomes in women with a prior low vertical uterine incision. An early study reported no significant difference in the risk of symptomatic uterine rupture during TOLAC for women with a prior low vertical incision versus those with a prior low transverse incision (0.8 versus 1.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/59\">",
"     59",
"    </a>",
"    ]. In contrast, a Maternal Fetal Medicine Units Network study found significant differences in the rates of uterine rupture during TOLAC by the type of previous hysterotomy incision [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/28\">",
"     28",
"    </a>",
"    ]. The rate of rupture by incision type was low transverse (0.7 percent), low vertical (2.0 percent), unknown (0.5 percent), and 1.9 percent in women who had a prior classical or inverted T- or J-incision and presented in advanced labor or declined repeat cesarean delivery.",
"   </p>",
"   <p>",
"    Among the authors and editors of this topic, one of four offers TOLAC to women with a prior low vertical uterine incision as long as there are no additional concerns, such as risk factors for difficult urgent cesarean delivery (eg, obesity, intraabdominal adhesions) or risk factors for placental insufficiency (eg, fetal growth restriction, oligohydramnios).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065580\">",
"    <span class=\"h4\">",
"     Multiple prior low-transverse uterine incisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review with meta-analysis of five cohort studies of uterine rupture in women with prior cesarean deliveries found that women undergoing TOLAC after two prior cesareans were at significantly higher risk of rupture than those with one prior cesarean (1.59 versus 0.72 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/60\">",
"     60",
"    </a>",
"    ]. The absolute risk of rupture after two cesareans was higher in all five studies, but the difference was not statistically significant in two of these five studies.",
"   </p>",
"   <p>",
"    Among the authors and editors of this topic, one of three offers TOLAC to women with two prior low transverse uterine incisions, as long as there are no additional concerns, such as risk factors for difficult urgent cesarean delivery (eg, obesity, intraabdominal adhesions) or risk factors for placental insufficiency (eg, fetal growth restriction, oligohydramnios).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065587\">",
"    <span class=\"h4\">",
"     Unknown type of uterine incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prior incision type is not always available when caring for a woman in her subsequent pregnancy. Because most women with a prior uterine incision for common obstetrical indications have had a low-transverse hysterotomy incision, some authors suggest making the decision for TOLAC based on this assumption. This approach is supported by data from a Maternal-Fetal Medicine Units Network study that found women who had an unknown type of prior incision had a similar rate of uterine rupture as those with a known prior low-transverse uterine incision (0.5 and 0.7 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are a few indications for cesarean delivery that increase the probability of a prior vertical incision, such as breech delivery remote from term or transverse lie, thus, the circumstances of the prior cesarean delivery should be considered in estimating whether the patient is at increased risk of uterine rupture.",
"   </p>",
"   <p>",
"    Among the authors and editors of this topic, one of three offers TOLAC to women with an unknown uterine incision, as long as there are no additional concerns, such as risk factors for difficult urgent cesarean delivery (eg, obesity, intraabdominal adhesions) or risk factors for placental insufficiency (eg, fetal growth restriction, oligohydramnios).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065594\">",
"    <span class=\"h4\">",
"     Pregnancy more than 40 weeks of gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently observed that women who attempt TOLAC beyond 40 weeks of gestation are less likely to successfully deliver vaginally [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/25,50,57,61\">",
"     25,50,57,61",
"    </a>",
"    ]. In addition, there are at least two reports that have described a 2 to 3 percent risk of rupture in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065601\">",
"    <span class=\"h4\">",
"     Multifetal gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most studies report that women with a twin gestation are significantly less likely to pursue a TOLAC, the overall success rate and risk of uterine rupture in this population is similar to that in singleton gestations undergoing TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5306?source=see_link&amp;anchor=H16#H16\">",
"     \"Twin pregnancy: Labor and delivery\", section on 'Trial of labor after previous cesarean delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065608\">",
"    <span class=\"h4\">",
"     Macrosomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of suspected macrosomia by any definition adds another factor to consider during decision-making for TOLAC versus ERCD. While most women with a previous cesarean delivery, a prior vaginal birth, and an estimated fetal weight of about 4000 g will have a successful TOLAC, we advise women with a macrosomic fetus and no prior history of a vaginal delivery against TOLAC because of a lower likelihood of success and a higher likelihood of adverse obstetrical outcomes, in particular, an increased risk of uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7074317\">",
"    <span class=\"h4\">",
"     Fetal demise",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/35/1591?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and management of stillbirth\", section on 'Options for women with a previous cesarean delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065615\">",
"    <span class=\"h3\">",
"     Inappropriate candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians believe the risks of TOLAC outweigh the benefits in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065622\">",
"    <span class=\"h4\">",
"     High-risk uterine scars",
"    </span>",
"    &nbsp;&mdash;&nbsp;Types of prior hysterotomy incisions that have an unacceptably high risk for uterine rupture with a TOLAC include: classical, T or J incisions, as well as transfundal incisions or myoma resections that extend into the myometrium. As discussed above, a Maternal Fetal Medicine Units Network study of TOLAC evaluated the outcome of women with prior classical or either inverted T or J incision who presented in advanced labor or declined repeat cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/28\">",
"     28",
"    </a>",
"    ]. These women had a uterine rupture rate of 1.9 percent. A subsequent retrospective study of women attempting TOLAC found that a prior inadvertent uterine extension at the time of primary cesarean was associated with an increased risk of uterine rupture when compared with no prior extension (6.0 versus 1.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065629\">",
"    <span class=\"h4\">",
"     Prior uterine rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have experienced a previous uterine rupture confined to the lower uterine segment are reported to have a high incidence (6 percent) of recurrent uterine rupture with labor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. Women in whom the prior rupture involved the upper uterine segment have experienced a repeat rupture rate as high as 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/69\">",
"     69",
"    </a>",
"    ]. In a 25-year literature review, 22 women identified to have uterine rupture subsequently became pregnant again [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/72\">",
"     72",
"    </a>",
"    ]. Twenty underwent ERCD at term; the other two women died following catastrophic uterine rupture at 32 and 35 weeks of gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=see_link&amp;anchor=H3#H3\">",
"     \"Repeat cesarean delivery\", section on 'Previous classical incision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If pregnancy is undertaken after repair of uterine rupture, it should be delayed a minimum of 18 to 24 months, given indirect evidence that a short interpregnancy interval has been associated with an increased risk of rupture in women undergoing TOLAC. Women with prior uterine rupture, prior Classical cesarean delivery, or prior hysterotomy for fetal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/74\">",
"     74",
"    </a>",
"    ] are all at increased risk of scar dehiscence or rupture in subsequent pregnancy and thus should undergo delivery by ERCD prior to term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=see_link&amp;anchor=H10#H10\">",
"     \"Interpregnancy interval and pregnancy outcome\", section on 'Uterine rupture during trial of labor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=see_link&amp;anchor=H3#H3\">",
"     \"Repeat cesarean delivery\", section on 'Previous classical incision'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44102?source=see_link&amp;anchor=H4106183#H4106183\">",
"     \"Rupture of the unscarred uterus\", section on 'Counseling about future pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065636\">",
"    <span class=\"h4\">",
"     Placenta previa, breech presentation, etc",
"    </span>",
"    &nbsp;&mdash;&nbsp;ERCD should be performed when standard obstetrical indications for cesarean delivery are present, such as placenta previa or footling breech presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9337101\">",
"    <span class=\"h4\">",
"     Lack of an appropriate facility",
"    </span>",
"    &nbsp;&mdash;&nbsp;ERCD should be performed when factors related to the facility, including availability of the surgical, anesthesia, nursing, and pediatric staff and resources to provide multiple transfusions of blood and blood products, preclude optimal care of the woman with ruptured uterus (see",
"    <a class=\"local\" href=\"#H15065658\">",
"     'Facilities and personnel'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065650\">",
"    <span class=\"h1\">",
"     LABOR AND DELIVERY CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065658\">",
"    <span class=\"h2\">",
"     Facilities and personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to perform emergency cesarean delivery is a prerequisite for attempting TOLAC in women with any type of prior hysterotomy incision. As discussed above, a joint statement of the ASA and ACOG stated that TOLAC should be undertaken only in facilities with immediate availability of appropriate resources, including equipment and personnel (obstetric anesthesia, nursing personnel, a physician capable of monitoring labor and performing an emergency cesarean delivery, personnel and equipment for neonatal resuscitation) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In situations in which such resources are not immediately available, ACOG recommends a discussion between the provider and patient to discuss implications of the lack of immediately available personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"     57",
"    </a>",
"    ]. One antepartum option is referral to another facility with appropriate resources to obtain optimal outcomes. In all cases, any decision to plan for TOLAC in the setting with lack of immediately available resources should be made only after careful consideration by the woman and her health-care provider. In such instances, the discussion and plan should be documented in the obstetrical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065665\">",
"    <span class=\"h2\">",
"     Induction and augmentation of labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits and harms of ERCD versus induction of labor have not been evaluated by randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there is no conclusive evidence that uterotonic drugs administered to women with a prior cesarean delivery increase the risk of uterine rupture, epidemiological studies suggest that this is the case. For this reason, we suggest a cautious approach to labor induction or augmentation in women undergoing TOLAC, especially those with an unknown type of uterine scar, unfavorable cervix, or gestational age over 40 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/50,76,77\">",
"     50,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065672\">",
"    <span class=\"h3\">",
"     Induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women who plan TOLAC will develop a maternal or fetal indication for delivery before the onset of labor. Two concerns about inducing labor in these women are observational studies that show an increased risk for uterine rupture with labor induction and a lower probability of successful TOLAC.",
"    <sup>",
"     &nbsp;",
"    </sup>",
"    A prior vaginal delivery or favorable cervix (eg, Bishop score of &gt;6) increases the probability of successful TOLAC with labor induction. The method of induction can also affect the outcome: induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    appears to have a lower risk for uterine rupture than prostaglandins. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28535?source=see_link\">",
"     \"Cervical ripening and induction of labor in women with a prior cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a practice bulletin, ACOG recognized induction of labor for maternal or fetal reasons as an option for women undergoing TOLAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"     57",
"    </a>",
"    ]. ACOG and others recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (prostaglandin E1)",
"    <strong>",
"     not",
"    </strong>",
"    be used for cervical ripening or labor induction in the third trimester in women with prior uterine incisions, and strongly discourage use of other prostaglandins, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57,78-81\">",
"     57,78-81",
"    </a>",
"    ]. If the cervix is dilated and favorable, our preference is to perform amniotomy to induce labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065686\">",
"    <span class=\"h3\">",
"     Augmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the risk of uterine rupture from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    augmentation of labor during TOLAC. Three large observational studies reported an increased risk for uterine rupture with labor augmentation (OR 2.3-14; actual rate of rupture 0.9-1.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/28,82,83\">",
"     28,82,83",
"    </a>",
"    ], and two others did not find an increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/29,84\">",
"     29,84",
"    </a>",
"    ]. Small numbers of uterine ruptures and use of prostaglandin analogues for cervical ripening prior to augmentation of labor prevent definitive conclusions based on these results.",
"   </p>",
"   <p>",
"    Despite a paucity of high-quality data, given the relative infrequency with which uterine rupture occurs, ACOG supports use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    for augmentation of labor in women with a previous cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065700\">",
"    <span class=\"h2\">",
"     Intrapartum monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given an increased risk of uterine rupture, most experts recommend continuous monitoring of uterine activity and fetal heart rate during TOLAC; there are no data to show superiority of external versus internal monitoring methods [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"     57",
"    </a>",
"    ]. Intrauterine pressure monitoring is unnecessary, as it is an insensitive method for early diagnosis of uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2557547\">",
"    <span class=\"h2\">",
"     Analgesia and anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural analgesia may be used to provide adequate pain relief during labor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065714\">",
"    <span class=\"h2\">",
"     Uterine exploration at delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians recommend routine uterine exploration following uncomplicated successful TOLAC, while others only perform exploration for standard obstetrical indications, such as retained placenta or hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/10/5290/abstract/87\">",
"     87",
"    </a>",
"    ]. There are no data on the value of routine examination to identify asymptomatic uterine dehiscence or whether repair is indicated.",
"   </p>",
"   <p>",
"    Among the authors and editors of this topic, two of three do not perform routine uterine exploration after vaginal delivery in women with a prior cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15065728\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women with a prior cesarean birth must choose between elective repeat cesarean delivery (ERCD) and a trial of labor after cesarean delivery (TOLAC). We feel the decision regarding mode of delivery must be made by each woman after informed discussion with her physician. The final assessment depends upon her individual clinical circumstances, tolerance for the various risks involved, and ability to give birth in a facility capable of emergency cesarean delivery if required. (See",
"      <a class=\"local\" href=\"#H15065253\">",
"       'Patient counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a hypothetical group of 100,000 women",
"      <strong>",
"       at term",
"      </strong>",
"      who undergo TOLAC rather than ERCD, there will be 10 fewer maternal deaths, 650 additional uterine ruptures, and 50 additional neonatal deaths. In terms of absolute risk for the woman undergoing TOLAC, 1 in 1000 trials of labor will result in neonatal death or significant neurological injury. Specifically, 1 in 100 trials will result in uterine rupture, and 1 in 10 uterine ruptures will result in neonatal death or neurological injury. (See",
"      <a class=\"local\" href=\"#H18437956\">",
"       'Overall estimated risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 75 percent of women who attempt TOLAC will be successful; this rate varies upon the clinical situation that led to the first cesarean birth. It is highest in women with a previous successful TOLAC, previous vaginal delivery, previous cesarean delivery for nonvertex presentation, and women with spontaneous onset of labor. The combination of previous cesarean for failure to progress or nonreassuring tracing, no previous vaginal delivery, and induced labor has a particularly poor prognosis. (See",
"      <a class=\"local\" href=\"#H15065260\">",
"       'Factors affecting success rate of TOLAC'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Williams JW. Obstetrics; A Textbook for the Use of Students and Practitioners, 1st ed, D Appleton &amp; Co, New York 1903.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/2\">",
"      Cragin, E. Conservatism in Obstetrics. NY J Med 1916; 104:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/3\">",
"      Kerr JMM. The lower uterine segment incision in conservative caesarean section. BJOG 2005; 28:475.",
"     </a>",
"    </li>",
"    <li>",
"     Eastman NJ. Williams Obstetrics, 10th ed, Appleton-Century-Crofts, New York 1950.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/5\">",
"      Pauerstein CJ. Once a section, always a trial of labor? Obstet Gynecol 1966; 28:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/6\">",
"      Pauerstein CJ, Karp L, Muher S. Trial of labor after low segment cesarean section. South Med J 1969; 62:925.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists: New guidelines to reduce repeat cesareans. Statement by Dr. Luella Klein for VBAC News Conference. ACOG (News Release), Washington, DC 1985.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Guidelines for Vaginal delivery after previous cesarean birth. Committee opinion No. 164. ACOG, Washington, DC 1988.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Vaginal delivery after previous cesarean birth. Committee opinion No. 143. ACOG, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/10\">",
"      Placek PJ, Taffel SM. Vaginal birth after cesarean (VBAC) in the 1980s. Am J Public Health 1988; 78:512.",
"     </a>",
"    </li>",
"    <li>",
"     Martin, JA, Hamilton, BE, Sutton, PD, et al. Births: Final Data for 2004. National Vital Statistics Reports. Vol 55; No.1 National Center for Health Statistics; Hyattsville, MD 2006.",
"    </li>",
"    <li>",
"     National Institutes of Health: Consensus Development Conference of Cesarean Childbirth, September 1980, sponsored by NICHD. NIH pub, No. 82-2067, NIH, Bethesda MD 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/13\">",
"      Jones RO, Nagashima AW, Hartnett-Goodman MM, Goodlin RC. Rupture of low transverse cesarean scars during trial of labor. Obstet Gynecol 1991; 77:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/14\">",
"      Scott JR. Mandatory trial of labor after cesarean delivery: an alternative viewpoint. Obstet Gynecol 1991; 77:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/15\">",
"      Sach BP, Koblin C, Castro MA. The risk of lowering the cesarean-delivery rate. N Engl J Med 1999; 340:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/16\">",
"      McMahon MJ, Luther ER, Bowes WA Jr, Olshan AF. Comparison of a trial of labor with an elective second cesarean section. N Engl J Med 1996; 335:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/17\">",
"      Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. N Engl J Med 2001; 345:3.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Vaginal delivery after previous cesarean delivery. Practice Bulletin No. 2. ACOG, Washington, DC 1998.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Vaginal delivery after previous cesarean section. Practice Bulletin No. 5. ACOG, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/20\">",
"      American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology 2007; 106:843.",
"     </a>",
"    </li>",
"    <li>",
"     American Society of Anesthesiologists. Optimal Goals For Anesthesia Care In Obstetrics-2008. ASA Standards, Guidelines and Statements. October 2007. file://www.asahq.org/publicationsAndServices/sgstoc.htm. (Accessed on May 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/22\">",
"      Martin JA, Hamilton BE, Sutton PD. Births: Final Data for 2006. Natl Vital Stat Rep 2009; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/23\">",
"      Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2007. Natl Vital Stat Rep 2010; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/24\">",
"      Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2008. Natl Vital Stat Rep 2010; 59:1, 3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/25\">",
"      National Institutes of Health Consensus Development Conference Panel. National Institutes of Health Consensus Development conference statement: vaginal birth after cesarean: new insights March 8-10, 2010. Obstet Gynecol 2010; 115:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/26\">",
"      Shihady IR, Broussard P, Bolton LB, et al. Vaginal birth after cesarean: do California hospital policies follow national guidelines? J Reprod Med 2007; 52:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/27\">",
"      Roberts RG, Deutchman M, King VJ, et al. Changing policies on vaginal birth after cesarean: impact on access. Birth 2007; 34:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/28\">",
"      Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 2004; 351:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/29\">",
"      Macones GA, Peipert J, Nelson DB, et al. Maternal complications with vaginal birth after cesarean delivery: a multicenter study. Am J Obstet Gynecol 2005; 193:1656.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologist. Overview of the 2009 ACOG Survey on Professional Liability. file://www.acog.org/About_ACOG/ACOG_Departments/Professional_Liability/2009_Survey_Results. (Accessed on May 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/31\">",
"      Clark SL, Belfort MA, Byrum SL, et al. Improved outcomes, fewer cesarean deliveries, and reduced litigation: results of a new paradigm in patient safety. Am J Obstet Gynecol 2008; 199:105.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/32\">",
"      Wells CE. Vaginal birth after cesarean delivery: views from the private practitioner. Semin Perinatol 2010; 34:345.",
"     </a>",
"    </li>",
"    <li>",
"     American Medical Association. 5 years of tort reform. Lone Star success story. file://www.ama-assn.org/amednews/2008/09/15/edsa0915.htm. (Accessed on May 21, 2012).",
"    </li>",
"    <li>",
"     Guise J-M, Eden K, Emeis C, Denman MA, Marshall N, Fu R, Janik R, Nygren P, Walker M, McDonagh M. Vaginal Birth After Cesarean: New Insights. Evidence Report/Technology Assessment No.191. (Prepared by the Oregon Health &amp; Science University Evidence-based Practice Center under Contract No. 290-2007-10057-I). AHRQ Publication No. 10-E003. Agency for Healthcare Research and Quality, Rockville, MD 2010. file://www.ahrq.gov/clinic/tp/cesarreqtp.htm#Report. (Accessed on May 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/35\">",
"      Landon MB, Leindecker S, Spong CY, et al. The MFMU Cesarean Registry: factors affecting the success of trial of labor after previous cesarean delivery. Am J Obstet Gynecol 2005; 193:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/36\">",
"      Gyamfi C, Juhasz G, Gyamfi P, Stone JL. Increased success of trial of labor after previous vaginal birth after cesarean. Obstet Gynecol 2004; 104:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/37\">",
"      Learman LA, Evertson LR, Shiboski S. Predictors of repeat cesarean delivery after trial of labor: do any exist? J Am Coll Surg 1996; 182:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/38\">",
"      Weinstein D, Benshushan A, Tanos V, et al. Predictive score for vaginal birth after cesarean section. Am J Obstet Gynecol 1996; 174:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/39\">",
"      Flamm BL, Geiger AM. Vaginal birth after cesarean delivery: an admission scoring system. Obstet Gynecol 1997; 90:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/40\">",
"      Bujold E, Blackwell SC, Hendler I, et al. Modified Bishop's score and induction of labor in patients with a previous cesarean delivery. Am J Obstet Gynecol 2004; 191:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/41\">",
"      Gonen R, Tamir A, Degani S, Ohel G. Variables associated with successful vaginal birth after one cesarean section: a proposed vaginal birth after cesarean section score. Am J Perinatol 2004; 21:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/42\">",
"      Grobman WA, Lai Y, Landon MB, et al. Development of a nomogram for prediction of vaginal birth after cesarean delivery. Obstet Gynecol 2007; 109:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/43\">",
"      King DE, Lahiri K. Socioeconomic factors and the odds of vaginal birth after cesarean delivery. JAMA 1994; 272:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/44\">",
"      Srinivas SK, Stamilio DM, Stevens EJ, et al. Predicting failure of a vaginal birth attempt after cesarean delivery. Obstet Gynecol 2007; 109:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/45\">",
"      Selo-Ojeme D, Abulhassan N, Mandal R, et al. Preferred and actual delivery mode after a cesarean in London, UK. Int J Gynaecol Obstet 2008; 102:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/46\">",
"      Kabir AA, Pridjian G, Steinmann WC, et al. Racial differences in cesareans: an analysis of U.S. 2001 National Inpatient Sample Data. Obstet Gynecol 2005; 105:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/47\">",
"      Srinivas SK, Stamilio DM, Sammel MD, et al. Vaginal birth after caesarean delivery: does maternal age affect safety and success? Paediatr Perinat Epidemiol 2007; 21:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/48\">",
"      Smith GC, White IR, Pell JP, Dobbie R. Predicting cesarean section and uterine rupture among women attempting vaginal birth after prior cesarean section. PLoS Med 2005; 2:e252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/49\">",
"      Stamilio DM, DeFranco E, Par&eacute; E, et al. Short interpregnancy interval: risk of uterine rupture and complications of vaginal birth after cesarean delivery. Obstet Gynecol 2007; 110:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/50\">",
"      Zelop CM, Shipp TD, Cohen A, et al. Trial of labor after 40 weeks' gestation in women with prior cesarean. Obstet Gynecol 2001; 97:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/51\">",
"      Cameron CA, Roberts CL, Peat B. Predictors of labor and vaginal birth after cesarean section. Int J Gynaecol Obstet 2004; 85:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/52\">",
"      DeFranco EA, Rampersad R, Atkins KL, et al. Do vaginal birth after cesarean outcomes differ based on hospital setting? Am J Obstet Gynecol 2007; 197:400.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/53\">",
"      Gregory KD, Korst LM, Cane P, et al. Vaginal birth after cesarean and uterine rupture rates in California. Obstet Gynecol 1999; 94:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/54\">",
"      Guise JM, Denman MA, Emeis C, et al. Vaginal birth after cesarean: new insights on maternal and neonatal outcomes. Obstet Gynecol 2010; 115:1267.",
"     </a>",
"    </li>",
"    <li>",
"     Cunningham, FG, Leveno KJ, et al. Williams Obstetrics, 23rd ed, Appleton-Century-Crofts, New York 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/56\">",
"      Eden KB, McDonagh M, Denman MA, et al. New insights on vaginal birth after cesarean: can it be predicted? Obstet Gynecol 2010; 116:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/57\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 115: Vaginal birth after previous cesarean delivery. Obstet Gynecol 2010; 116:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/58\">",
"      Scott JR. Vaginal birth after cesarean delivery: a common-sense approach. Obstet Gynecol 2011; 118:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/59\">",
"      Shipp TD, Zelop CM, Repke JT, et al. Intrapartum uterine rupture and dehiscence in patients with prior lower uterine segment vertical and transverse incisions. Obstet Gynecol 1999; 94:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/60\">",
"      Tahseen S, Griffiths M. Vaginal birth after two caesarean sections (VBAC-2)-a systematic review with meta-analysis of success rate and adverse outcomes of VBAC-2 versus VBAC-1 and repeat (third) caesarean sections. BJOG 2010; 117:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/61\">",
"      Coassolo KM, Stamilio DM, Par&eacute; E, et al. Safety and efficacy of vaginal birth after cesarean attempts at or beyond 40 weeks of gestation. Obstet Gynecol 2005; 106:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/62\">",
"      Kiran TS, Chui YK, Bethel J, Bhal PS. Is gestational age an independent variable affecting uterine scar rupture rates? Eur J Obstet Gynecol Reprod Biol 2006; 126:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/63\">",
"      Hammoud A, Hendler I, Gauthier RJ, et al. The effect of gestational age on trial of labor after Cesarean section. J Matern Fetal Neonatal Med 2004; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/64\">",
"      Cahill A, Stamilio DM, Par&eacute; E, et al. Vaginal birth after cesarean (VBAC) attempt in twin pregnancies: is it safe? Am J Obstet Gynecol 2005; 193:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/65\">",
"      Elkousy MA, Sammel M, Stevens E, et al. The effect of birth weight on vaginal birth after cesarean delivery success rates. Am J Obstet Gynecol 2003; 188:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/66\">",
"      Zelop CM, Shipp TD, Repke JT, et al. Outcomes of trial of labor following previous cesarean delivery among women with fetuses weighing &gt;4000 g. Am J Obstet Gynecol 2001; 185:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/67\">",
"      Jastrow N, Roberge S, Gauthier RJ, et al. Effect of birth weight on adverse obstetric outcomes in vaginal birth after cesarean delivery. Obstet Gynecol 2010; 115:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/68\">",
"      Goldfarb I, Henry D, Dumont O. Inadvertant hysterotomy extension at cesarean delivery and risk of uterine rupture in the next pregnancy. Am J Obstet Gynecol 2011; 204:S266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/69\">",
"      Ritchie EH. Pregnancy after rupture of the pregnant uterus. A report of 36 pregnancies and a study of cases reported since 1932. J Obstet Gynaecol Br Commonw 1971; 78:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/70\">",
"      Reyes-Ceja L, Cabrera R, Insfran E, Herrera-Lasso F. Pregnancy following previous uterine rupture. Study of 19 patients. Obstet Gynecol 1969; 34:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/71\">",
"      Sajjad Y, Sharma SD, Thomas K. Three consecutive uterine ruptures in the same woman, each with fetal survival. BJOG 2005; 112:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/72\">",
"      Chibber R, El-Saleh E, Al Fadhli R, et al. Uterine rupture and subsequent pregnancy outcome--how safe is it? A 25-year study. J Matern Fetal Neonatal Med 2010; 23:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/73\">",
"      Soltan MH, Khashoggi T, Adelusi B. Pregnancy following rupture of the pregnant uterus. Int J Gynaecol Obstet 1996; 52:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/74\">",
"      Wilson RD, Lemerand K, Johnson MP, et al. Reproductive outcomes in subsequent pregnancies after a pregnancy complicated by open maternal-fetal surgery (1996-2007). Am J Obstet Gynecol 2010; 203:209.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/75\">",
"      Dodd JM, Crowther CA. Elective repeat caesarean section versus induction of labour for women with a previous caesarean birth. Cochrane Database Syst Rev 2006; :CD004906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/76\">",
"      Hickman MA. The MFMU cesarean registry: Risk of uterine rupture in women attempting VBAC with an unknown uterine scar. Am J Obstet Gynecol 2008; 199:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/77\">",
"      Grubb DK, Kjos SL, Paul RH. Latent labor with an unknown uterine scar. Obstet Gynecol 1996; 88:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/78\">",
"      Bennett BB. Uterine rupture during induction of labor at term with intravaginal misoprostol. Obstet Gynecol 1997; 89:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/79\">",
"      Wing DA, Lovett K, Paul RH. Disruption of prior uterine incision following misoprostol for labor induction in women with previous cesarean delivery. Obstet Gynecol 1998; 91:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/80\">",
"      Plaut MM, Schwartz ML, Lubarsky SL. Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Am J Obstet Gynecol 1999; 180:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/81\">",
"      Aslan H, Unlu E, Agar M, Ceylan Y. Uterine rupture associated with misoprostol labor induction in women with previous cesarean delivery. Eur J Obstet Gynecol Reprod Biol 2004; 113:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/82\">",
"      Zelop CM, Shipp TD, Repke JT, et al. Uterine rupture during induced or augmented labor in gravid women with one prior cesarean delivery. Am J Obstet Gynecol 1999; 181:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/83\">",
"      Dekker GA, Chan A, Luke CG, et al. Risk of uterine rupture in Australian women attempting vaginal birth after one prior caesarean section: a retrospective population-based cohort study. BJOG 2010; 117:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/84\">",
"      Flamm BL, Goings JR, Fuelberth NJ, et al. Oxytocin during labor after previous cesarean section: results of a multicenter study. Obstet Gynecol 1987; 70:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/85\">",
"      Devoe LD, Croom CS, Youssef AA, Murray C. The prediction of \"controlled\" uterine rupture by the use of intrauterine pressure catheters. Obstet Gynecol 1992; 80:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/86\">",
"      Rodriguez MH, Masaki DI, Phelan JP, Diaz FG. Uterine rupture: are intrauterine pressure catheters useful in the diagnosis? Am J Obstet Gynecol 1989; 161:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/10/5290/abstract/87\">",
"      Lurie S, Hagay Z, Goldschmit R, Insler V. Routine previous cesarean scar exploration following successful vaginal delivery. Is it necessary? Eur J Obstet Gynecol Reprod Biol 1992; 45:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4479 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5290=[""].join("\n");
var outline_f5_10_5290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15065728\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15065246\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15065253\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15065260\">",
"      FACTORS AFFECTING SUCCESS RATE OF TOLAC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065269\">",
"      Antepartum factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9335477\">",
"      - Indication for prior cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9335484\">",
"      - History of prior vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065277\">",
"      - Demographic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065298\">",
"      - Maternal medical disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065305\">",
"      Intrapartum factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065313\">",
"      - Admission labor status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065320\">",
"      - Fetal macrosomia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065327\">",
"      - Type of hospital",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15065383\">",
"      RISKS AND BENEFITS OF TOLAC AND ERCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18437956\">",
"      Overall estimated risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065390\">",
"      Maternal risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065481\">",
"      Maternal benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065488\">",
"      Perinatal risks and benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065495\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065502\">",
"      - Hypoxic ischemic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065509\">",
"      - Respiratory problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065516\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18438373\">",
"      OPTIMUM CANDIDATES FOR TOLAC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18438126\">",
"      Screening tools and decision aids for choosing the route of delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18438133\">",
"      - Provider screening tools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18438140\">",
"      - Patient decision aids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065552\">",
"      Recommendations by national organizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18441899\">",
"      - Appropriate candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065559\">",
"      One prior low transverse uterine incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065566\">",
"      - Possibly appropriate candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065573\">",
"      Prior low vertical uterine incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065580\">",
"      Multiple prior low-transverse uterine incisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065587\">",
"      Unknown type of uterine incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065594\">",
"      Pregnancy more than 40 weeks of gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065601\">",
"      Multifetal gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065608\">",
"      Macrosomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7074317\">",
"      Fetal demise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065615\">",
"      - Inappropriate candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065622\">",
"      High-risk uterine scars",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065629\">",
"      Prior uterine rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15065636\">",
"      Placenta previa, breech presentation, etc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9337101\">",
"      Lack of an appropriate facility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15065650\">",
"      LABOR AND DELIVERY CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065658\">",
"      Facilities and personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065665\">",
"      Induction and augmentation of labor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065672\">",
"      - Induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15065686\">",
"      - Augmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065700\">",
"      Intrapartum monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2557547\">",
"      Analgesia and anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15065714\">",
"      Uterine exploration at delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15065728\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4479|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/59/30654\" title=\"figure 1\">",
"      Cesarean delivery rates in the US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/36/10828\" title=\"table 1\">",
"      Counseling women with a prior cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/0/4108\" title=\"table 2\">",
"      Factors associated with trial of labor after cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/62/26604\" title=\"table 3\">",
"      Evidence for maternal outcomes from TOLAC versus ERCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/22/43372\" title=\"table 4\">",
"      ACOG on vaginal birth after cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/41/28316\" title=\"table 5\">",
"      TOLAC recommendations of professional societies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28535?source=related_link\">",
"      Cervical ripening and induction of labor in women with a prior cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=related_link\">",
"      Cesarean delivery: Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/35/1591?source=related_link\">",
"      Diagnosis and management of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=related_link\">",
"      Interpregnancy interval and pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=related_link\">",
"      Repeat cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44102?source=related_link\">",
"      Rupture of the unscarred uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5306?source=related_link\">",
"      Twin pregnancy: Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=related_link\">",
"      Uterine rupture after previous cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_10_5291="GnRH agonist dosing";
var content_f5_10_5291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended doses for GnRH-agonists",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Trade name",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Route of administration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Goserelin acetate",
"      </td>",
"      <td>",
"       Zoladex",
"      </td>",
"      <td>",
"       3.6 milligrams every 28 days",
"      </td>",
"      <td>",
"       Subcutaneous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Leuprolide acetate",
"      </td>",
"      <td rowspan=\"2\">",
"       Lupron",
"      </td>",
"      <td>",
"       3.75 milligrams once per month",
"      </td>",
"      <td>",
"       Intramuscular",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11.25 milligrams every three months",
"      </td>",
"      <td>",
"       Intramuscular",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nafarelin acetate",
"      </td>",
"      <td>",
"       Synarel",
"      </td>",
"      <td>",
"       200 micrograms twice daily",
"      </td>",
"      <td>",
"       Intranasal",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5291=[""].join("\n");
var outline_f5_10_5291=null;
var title_f5_10_5292="Antiemetics by etiology";
var content_f5_10_5292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selection of antiemetics by clinical situation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Situation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated neurotransmitters",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended antiemetic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Migraine headache",
"       </td>",
"       <td rowspan=\"2\">",
"        Dopamine (probably a primary mediator)",
"       </td>",
"       <td>",
"        For headache and nausea: metoclopramide (reglan) or prochlorperazine (compazine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For nausea: oral antiemetics, metoclopramide, prochlorperazine, serotonin antagonists",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vestibular nausea",
"       </td>",
"       <td>",
"        Histamine, acetylcholine",
"       </td>",
"       <td>",
"        Antihistamines and anticholinergics (equally effective)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Pregnancy-induced nausea",
"       </td>",
"       <td rowspan=\"2\">",
"        Unknown",
"       </td>",
"       <td>",
"        For nausea: ginger, vitamin B6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For hyperemesis gravidarum: promethazine (phenergan, first-line agent); serotonin antagonists and corticosteroids (second-line agents)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Gastroenteritis",
"       </td>",
"       <td rowspan=\"3\">",
"        Dopamine, serotonin",
"       </td>",
"       <td>",
"        First-line agents: dopamine antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Second-line agents: serotonin antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use in children is controversial",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Postoperative nausea and vomiting",
"       </td>",
"       <td rowspan=\"2\">",
"        Dopamine, serotonin",
"       </td>",
"       <td>",
"        Prevention: serotonin antagonists, droperidol (inapsine), dexamethasone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment: dopamine antagonists, serotonin antagonists, dexamethasone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician 2004; 69:1169.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5292=[""].join("\n");
var outline_f5_10_5292=null;
var title_f5_10_5293="Medical hx chronic diarrhea";
var content_f5_10_5293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Implications of some aspects of the medical history in patients with chronic diarrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Line of questioning",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical implication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Congenital",
"       </td>",
"       <td class=\"sublist_other\">",
"        Chloridorrhea, Na+ malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abrupt",
"       </td>",
"       <td class=\"sublist_other\">",
"        Infections, idiopathic secretory diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gradual",
"       </td>",
"       <td class=\"sublist_other\">",
"        Everything else",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history",
"       </td>",
"       <td>",
"        Congenital absorptive defects, IBD, celiac disease, multiple endocrine neoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Dietary history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        \"Sugar-free\" foods",
"       </td>",
"       <td class=\"sublist_other\">",
"        Sorbitol, mannitol ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Raw milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        Brainerd diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to potentially impure water source",
"       </td>",
"       <td>",
"        Chronic bacterial infections (eg, Aeromonas), giardiasis, cryptosporidiosis, Brainerd diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Travel history",
"       </td>",
"       <td>",
"        Infectious diarrhea, chronic idiopathic secretory diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"       <td>",
"        Malabsorption, pancreatic exocrine insufficiency, neoplasm, anorexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous therapeutic interventions (drugs, radiation, surgery, antibiotics)",
"       </td>",
"       <td>",
"        Drug side effects, radiation enteritis, postsurgical status, pseudomembranous colitis, post-cholecystectomy diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary gain from illness",
"       </td>",
"       <td>",
"        Laxative abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic illness symptoms",
"       </td>",
"       <td>",
"        Hyperthyroidism, diabetes, vasculitis tumors, Whipple's disease, inflammatory bowel syndrome, tuberculosis, mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous drug abuse, sexual promiscuity",
"       </td>",
"       <td>",
"        AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune problems",
"       </td>",
"       <td>",
"        AIDS, immunoglobulin deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"       <td>",
"        Mesenteric vascular insufficiency, obstruction, irritable bowel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive flatus",
"       </td>",
"       <td>",
"        Carbohydrate malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leakage of stool",
"       </td>",
"       <td>",
"        Fecal incontinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Stool characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blood",
"       </td>",
"       <td class=\"sublist_other\">",
"        Malignancy, inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oil/food particles",
"       </td>",
"       <td class=\"sublist_other\">",
"        Malabsorption, maldigestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        White/tan color",
"       </td>",
"       <td class=\"sublist_other\">",
"        Celiac disease, absence of bile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nocturnal diarrhea",
"       </td>",
"       <td class=\"sublist_other\">",
"        Organic etiology",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5293=[""].join("\n");
var outline_f5_10_5293=null;
var title_f5_10_5294="Alosetron and IBS";
var content_f5_10_5294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Benefit of alosetron in diarrhea-predominant IBS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 289px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of a controlled trial of 647 women with irritable bowel syndrome (IBS) that was either diarrhea-predominant or had alternating diarrhea and constipation. The women were randomly assigned to alosetron (1 mg twice daily) or placebo for 12 weeks. A significantly greater proportion of women treated with alosetron (41 verses 29 percent with placebo) described adequate relief for all three months of therapy. This difference disappeared with cessation of therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Camilleri, M, Northcutt, AR, Kong, S, et al. Lancet 2000; 355:1035.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5294=[""].join("\n");
var outline_f5_10_5294=null;
var title_f5_10_5295="Endoscopy showing Schatzki ring dilation";
var content_f5_10_5295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schatzki ring dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic imaging showing balloon dilation of the distal esophageal ring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Douglas A. Horst, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_10_5295=[""].join("\n");
var outline_f5_10_5295=null;
